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A Introduction 
 
1. The Importance of Drug Discovery 
 
To meet the growing demands of molecules for the discovery of new drugs, organic 
chemists have developed novel techniques and explored new reaction mechanisms and 
strategies to efficiently carry out organic transformations. Based on the vast traditional 
practice to combat a variety of malignant and infectious diseases, natural products play a 
pivotal role in the search and development of new drugs entities. From their vast 
repertoire, organic chemists have been able to invent, design and synthesize unnatural 
molecules to predict their properties in vivo or vitro, and subsequently providing modern 
therapeutic drugs in highly effective ways. 
The need to discover drugs and to create de novo designer molecules is steadily growing. 
It is noteworthy to realize that instead of creating new molecules in million by 
combinatorial chemistry, it is better to design new molecules by  emulating the basics of  
information showed provided by nature.
1
 Moreover chemical synthesis will be a key 
technology of progress in medicine and human health during the 21
st
 century.
2
  
Therefore studies in the area of chemical syntheses and drug discovery will make 
enormous contributions to human health. 
 
1.1 Oxygen Heterocycles with -butyrolactone 
 
 
Heterocyclic compounds are present in a majority of natural products. Most of natural 
products with heterocyclic ring structures exhibit biological activity.  Oxygen 
heterocyclic compounds bearing a -butyrolactone ring system have attracted  
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considerable attention during the last two decades due to their diverse medicinal 
properties such as antibiotic,
3
 antitumor,
4
 antifungal, antibacterial,
5
 antileukemia
6
 , 
glaucoma 
7
 and many more. 
-butyrolactone are also versatile synthons for synthesizing more complex medicinally 
important compounds such as bacilosarsin A
8
, an antibiotic with potent herbicidal 
activity, trans-burseran
9
 for antileukemia treatment and microsclerodermins which 
display potent antifungal and antiproliferative activities. Some natural products with -
butyrolactone ring system are depicted in Figure 1. 
 
OO
OO R
R = CH(OH)C12H25  : (+) Muricatacin
OO
CH3
R
R = C4H9  : (+)- Whisky lactone
      C5H11 : (+)- Cognaae lactone
      CH2CHC(CH3)2 : (+)-EldanolideOO
H3C COOH
R
R = C11H23 : (+)-Nephrosteranic acid
      C13H27 : (+)-Roccellaric acid
      (CH2)13CH(OH)CH3 : Neodihydromuroic acid
      (CH2)4Me : Phaseolinic
OO
COOH
R
R = C13H27 : Protolichesterini
                   acid
 C5H11 : Methylenolactocin
OO
.HCl
N
Geissman Weiss Lactone
 
 
Figure 1: Compounds with -butyrolactone ring system 
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1.2        Sugar Amino Acids 
 
Carbohydrate scaffolds with both a carboxylic acid and an amine functionality, the so-
called sugar amino acids (SAAs) have served as building blocks for the synthesis of 
oligopeptides.
8
 
Sugar amino acids are present in nature as construction elements in bacteria. The most 
abundant naturally occurring SAAs is sialic acid which is often located in the periphery 
of glycoproteins. These natural SAAs consist of N- and O-acyl derivatives of neuraminic 
acid derivatives 1. Several others example of natural SAAs are glucosaminuronic acid  2,  
found in bacterial cell walls,
9
 4-amino-4-deoxy-glucuronic acid 3, found in antibiotic 
isolated from Streptomyces bacteria
10
 and (+)-hydantocidin 4, which represents a 
spirohydanthion derivatives
11
 and siastatin 5 which was isolated from a Streptomyces 
culture
12
, act as  inhibitor for both  -glucuronidase and N-acetylneuraminidase.  Their 
molecule structures are depicted in Figure 2. 
O
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O
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O
O
HO
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Figure 2: Natural occurring of sugar amino acids 
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Fleet and coworkers reported the synthesis of -SAAs 6, 7, 8, 9, several azide precursors 
of  -SAAs 10, 11, 12, 13 and -SAAs  15, 16 as depicted in Figure 3. 
 
O CO2H
NH2
OSiMe2tBuButMe2SiO
O
O
O NH2
CO2H
OSiMe2tBuButMe2SiO
O
O
O NH2
CO2H
O
O
O O
O CO2H
NH2
O
O
O O
O CO2H
N3HO
HO
O CO2H
N3HO
HO
O CO2H
N3HO
HO
O CO2H
HO
HO
N3
O
OTBDMS
OTBDPS
N3
HO2C
O
OTBDMS
CO2H
N3
HO
O
OTBDMS
CO2H
N3
HO
OH
6 7 8 9
10 11
12 13
14
15 16
 
 
Figure 3: Fleet’s large collection of ,  and -SAAs 
 
 
Several research groups have also synthesized furanoid - SAAs such as Le Merrer’s,13 
Fleet’s14 and Charkraborty’s 15 and their molecules structure are depicted in Figure 4. 
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Figure 4: Some of  Le Merrer’s, Fleet’s and Charkraborty’s furanoid  - SAAs 
 
 
There are several advantages of SAAs as building blocks: Firstly,  the rigid 
conformations of SAAs make them ideal candidates as non-peptide scaffolds in 
peptidomimetics where they can be incorporated into linear or cyclic oligopeptides by 
using their carboxyl and amino termini. Secondly, the presence of several chiral centers  
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in furanoid SAAs, can give rise to a large number of possible isomers that can be used to 
create combinatorial libraries of SAAs. Finally, the protected or unprotected hydroxyl  
 
groups of SAAs rings can also influence the hydrophobic or hydrophilic nature of  the 
molecules.
16
 Incorporation of SAAs in a peptide chain, or for instance as a replacement of 
a natural peptide segment, may create a more stable unnatural peptide under physiologic 
conditions since peptidases and proteases do not recognize those. 
 
1.3 Objectives of Research 
 
The aim of this study is to develop a novel cis--butyrolactone amino acid and its 
utilization as a building block in peptides, moreover, the syntheses of chiral intermediates 
being relevant for natural products synthesis is also intended. Therefore, the objectives of 
this study are as follows: 
(1) To develop new methodology for the synthesis of (-)-Geissman Waiss Lactone 
(GWL). 
(2) To synthesize cis--butyrolactone amino esters and their corresponding amino 
acids. 
(3) To synthesize dipeptides and tetrapeptides based on a cis--butyrolactone 
scaffold. 
(4) To evaluate the antituberculosis ability of some of the synthesized cis--
butyrolactone amino type compounds. 
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B.  Enantioselective synthesis of (-)- Geissman Waiss Lactone 
as Synton to Retronecine 
  
 
1.  Introduction 
 
 
Retronecine is found widely in numerous alkaloids such as senecionine, seneciphylline 
and retrorsine. It belongs to the pyrrolizidine type alkaloids, which are also found in 
many plants. Extracts of plants containing these alkaloids have been used in traditional 
herbal medicine.
1
 Many of these alkaloids show interesting biological activities including 
hepatotoxic, antitumor, hypotensive, anti-inflammatory and antispasmolytic activities.
2
 In 
addition, a epimer of retronecine found in nature is heliotridine  with an invered 
configuration on  C-8 (Figure 5). Other known necine bases of interest are turneforcidine, 
platynecine and coralbinecine. 
Due to the intriguing diverse chemical structures and their characteristic pharmacologic 
bioactivities, a lot of efforts have been directed towards the synthesis of these alkaloids 
(Figure 5).  
   
N
CH2OHHHO
N
CH2OHHOH
H
N
CH2OHHO
CH2OHHHO
OH
N
HHO
N
CH2OH
Retronecine Heliotridine
1
2
35
6
7 8
CoralbinecineTurneforcidine Platynecine  
Figure 5: Examples of pyrrolizidine bases with retronecine backbone. 
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2. Synthesis of Retronecine 
 
Syntheses of retronecine have been reported by different research groups led by 
Geissman, Naraska and Ruger. In 1962, Geissman reported  the synthesis of racemic 
retronecine ±-24a  from racemic GWL ±-27a.
3
 Geissman showed that retronecine ±-24a 
could be derived from 7-hydroxypyrrolizidine-1-carboxylate ±-25, which could be in turn 
be prepared  from ethyl-2,7-dihydroxypyrrolizidine-1-carboxylate ±-26. N-protected (±)-
GWL ±-27b could be used to prepare ±-26 (Scheme 1). 
 
N
CH2OHHO
N
CH2ORHO
R = H, Et
N
CH2OEtHO H
OH
O
N
O
R
24a 25 26
27a  R = H
27b  R = CH2COOEt
 
 
Scheme 1: Retrosynthesis towards retronecine developed by Geissman  
 
Rueger and co-workers reported a new approach towards the syntheses of retronecine 
24a, coralbinecine 24c and platynecine 24d. Rueger showed that these necine bases could 
be derived from the very versatile building block lactone known as (+)-Geissman-Waiss 
Lactone 27a.
4 
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R
N
O O
N
H
CH2OHHO
CH2OHHO
N
H
OH
H
N
CH2OHHO
Platynecine
Retronecine
Coralbinecine
R
SR
R
R
R
 27a R= H
27c    R= Cbz
27d    R= Boc
24b
24c
24d
S
S
R
 
   
Figure 6: Necine bases synthesized from Geissman-Weiss Lactone developed by Rueger. 
 
 
In this route, Rueger demonstrated that alkylation of (+)-GWL 27a gives N-alkylated 
GWL 27b, which was then subjected to Dieckmann condensation followed by catalytic 
hydrogenation to afford dihydroxy ester 29. Treatment of dihydroxy ester 29 with acetic 
anhydride to protect the hydroxyl groups gave 30, followed by base induced elimination 
to 31. Saponification and reduction finally to give the corresponding retronecine 24b 
(Scheme 2). 
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O
N
O
R
R = H
N
O
COOEtHO
N
OH
COOEtHOH H
N
OAc
COOEtAcO H
N
COOEtAcO H
N
CH2OHHO H
27a
28 29
30 31 24b
27b R = CH2COOEt
 
 
 
Scheme 2: Synthesis of retronecine developed by Rueger et. al 
 
 
3.         Several known synthetic strategy to (-)- Geissman Weiss Lactone 
 
 
GWL was first synthesized in 1962 by Geissman and Waiss,
3
  from  -unsaturated 
ester and amino ester.  However they only synthesized racemic GWL and racemic 
retronecine. 
Consequently, the development of new methods for the synthesis of GWL has received 
considerable attention. In 1999, the syntheses of two diastereoisomers of GWL ie (+)- 
GWL 36a and (-)-GWL 36b were achieved via Miranda methodology by applying a 
[2+2] cycloaddition reaction in the presence of chiral auxiliaries on enecarbamate.
5
  
Enecarbamate 32 after treatment with dichloroketene 33 via [2+2] cycloaddition reaction 
in triethylamine was transformed into aza-bicyclic cyclobutanones 34 in 63% yield.  
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Subsequently dechlorination and ring expansion of 35 through Bayer Villager oxidation 
to provide the corresponding GWL 36a or 36b in 71% as depicted in Scheme 3. 
 
O
NO
2 +2
O
C
Cl Cl
O
NO
Cl
Cl
O
Zn-Cu
NH4Cl
MeOH
rt.
O
NO
O
62%
m-CPBA
CH2Cl2
NaHCO3
0
 o
C, 
71%
OO
.HCl
N
(+)-GWL
OO
.HCl
N
or
63%32 34 35
(-)- GWL
36a 36b
33
 
Scheme 3: Syntheses of (+) and (-)-GWL developed by Miranda et al. 
Huang et al. developed a methodology to (+)-GWL starting from (S)-malimide 37.
6
 
Selective reductive alkylation of protected (S)-malimide 37 by organolithium in ethyl 
acetate, gave 38 in high C-2 regioselectivity. Treatment of N,O-acetal  38  with  
BF3.OEt2/triethylsilane led to lactam 39. Subsequent debenzylation of 39 under 
hydrogenation conditions afforded hydroxyl lactam 40.  Successive saponification of 40  
and intramolecular Mitsunobu reaction (PPh3, DEAD, CH2Cl2) gave lactone 42. The 
chemoselective deoxygenation reduction of 42 was achieved by treating with borane  
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dimethylsulfide in THF yielding cis-pyrolidine lactone 43 in 58%. The (+)-GWL 36a was 
obtained by deprotection of PMB with Pd/C under hydrogenolytic conditions (Scheme 4). 
N O
PMB
O
BnO
(S)- malimide
LHMDS, AcOEt
N
O
PMB
BnO
HO
EtO2C
Et3SiH
BF3.OEt2
CH2Cl2, -78
 o
C
86%
N
O
PMB
BnO
EtO2C
H2, 10% Pd/C
N
O
PMB
HO
EtO2C
LiOH, H2O
N O
PMB
HO
HOOC
PPh3, DEAD
N O
PMB
O
O
H3B-SMe2
N
PMB
O
OH2, 10% Pd/C
N
H2Cl
O
O
THF, -78
 o
C
89%
EtOH
87%
rt.
0
 o
C-rt.
96% from Comp 40
THF, 24h
58%
MeOH, 95%
37 38
39 40
41424336a
 
Scheme 4: Synthesis of (+)-GWL from (S)-malimide 
 
Niwa et al. synthesized (-)-N-(ethoxycarbonyl) methyl GWL 27b starting  from R-(+)-
malic acid 44.
7
 Treatment of malic  acid 44 with acetyl chloride and glycine ethyl ester 
afforded imide 45 followed by hydrolysis to give the hydroxyl imide 46. 
Bromoacetylation of 46 in ether gave bromoacetoxy imide 47. Reaction of 47 with 
triphenylphosphine in acetonitrile furnished phosphonium salt 48, which was treated with 
triethylamine to give lactone 49. Hydrogenation of 49 afforded the lactone lactam, which  
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by reduction of the lactam group using Lawesson reagent gave the thiolactam which then 
undergoes reduction with triethyloxonium tetrafluroborate and sodium cyanoborohydrate 
to give the product as depicted in Scheme 5. 
(R)-malic acid
CH3COCl, CH2Cl2
Glycine ethyl ester
N
O
O
COOEt
AcO
N
O
O
COOEt
HO
BrCH2CBr
O
Py, 0
 o
C N
O
O
COOE
t
O
BrO
PPh3
MeCN
N
O
O
COOEt
O
pph3
+
 Br
-ONet3/ 50
 o
C
N
O
O
O
COOEtN
O O
COOEt
HO
O
O
OH
OH
ClH2N
O
OH
hydrolysis
50
 o
C
97%
92%
99%
92%
44 45 46
47
48
4927b
 
Scheme 5: Synthesis of (+)-GWL 27b developed by Niwa and coworkers. 
 
Cooper and co-workers reported that (-)-GWL 36b could be derived from keto proline 
50. According to their report, yeast reduction (dried Baker yeast, sucrose, water, 30 
o
C, 
24 h) yielded hydroxy proline 51 in 75% and in single diastereoisomer.
8
 Acetylation of 
51, followed by Arndt-Eistert  homologation provided the homologous ester 53, which  
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upon base hydrolysis of 53 followed by treatment with the acid furnished (-)-GWL 36b 
as depicted in Scheme 6. 
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Scheme 6: Synthesis of (-) GWL from keto proline developed by Cooper and coworkers. 
 
Also in this regard, Wee reported intramolecular C-H insertion reaction of chiral 
diazoacetates catalyzed by dirohodium-(II) tetrakis[methyl (5R and 5S)-3 
phenylpropanoyl-2 imidazolidinone-5-carboxylate]
9
 for the synthesis of (-) and (+) GWL 
as depicted in Scheme 7. Wee et al synthesized (-)-GWL starting from (R)-3-pyrolidinol 
54. Treatment of (R)-3-pyrolidinol 54 with benzyl chloroformate to protect N terminal 
gave N-Cbz-3- hydroxy pyrroline 55. Inversion of hydroxyl group of 55 under Mitsonobu 
condition afforded 56 and acylation of the latter by Corey-Myers method gave  
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diazoacetate 57. By applying Rh(II) catalyzed reaction, 57 could be  transformed to (-)-
GWL. The (+)-GWL also could be envisioned by this protocol.  
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N
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Scheme 7: Synthesis of (+) and (-) GWL via intramolecular C-H insertion developed by 
Wee 
Lactone lactam is a useful synton for the synthesis of GWL. Jouin et al discovered that  
lactone lactam could be obtained form N-protected amino acid .
10
 The reaction between 
N-protected amino acid 59 and cyclic diester 60 afforded  the tetramic 61, which was then 
transformed to cyclic statine 62  by hydrogenation. The latter was transformed 
spontaneously to N-protected lacton lactam 63a as depicted in Scheme 8. 
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Scheme 8: Synthesis of lactone lactam from N-protected amino acid  
 
 
4. Retrosynthesis analysis of (-)- lacton lactam 63a 
 
 
The (-)-lactone lactam 63a, can in principle be derived from benzene 69. Benzene was 
envisioned to be transformed to 1,4–cyclohexadiene 68, then epoxidation of - 1,4-
cyclohexadiene 68, followed by enantioselective asymmetric ring opening of the epoxide 
67, reduction amination sequence and Boc protection of 66. Ozonolysis of N-Boc 
protected amine 65 should give dialdehyde  64 which is then easily converted into the 
desired  (-)- lactone lactam 63a by Jones oxidation (Scheme 9 ). 
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First strategy 
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Scheme 9. Retrosynthetic analysis of (-)- lacton lactam 
 
 
 
Second strategy towards (-)-lactone lactam can also be synthesized from N-Boc protected 
amine 65. Oxidative cleavage of 65 by ruthenium tetraoxide in the presence of sodium 
periodate should give spontaneously (-)-lactone lactam 63a. 
 
 
5.  Synthesis  outline towards  (-)-lactone lactam 63a 
 
 
5.1  Birch reduction and epoxidation 
 
Benzene 69 was reduced into 1,4–cyclohexadiene 68 via Birch reduction with liquid NH3 
and sodium metal. Epoxidation of 1,4–cyclohexadiene 68 with m-CPBA (1 equiv.)  in the  
CHAPTER B  
20 
 
Enantioselective synthesis of (-)-Geissman Waiss Lactone as a synthon to retronecine 
presence of K2HPO4 yielded 1,4-cyclohexadiene monoxide 67 as the major product 
(89%), while the corresponding diepoxide
11
 was found in minor amounts (8%) as 
depicted in Scheme 10. Epoxides are valuble intermediates for the stereocontrolled 
synthesis of complexs natural products compounds. Havingsuccessfully prepared epoxide 
67, our next attempt was to open the epoxide ring  enantioselectively to obtain the 
requisite olefinic product  66. 
O
a b
69 68 67  
 
Reagent and condition : (a) Na, Liq. NH3, EtOH, -78 
o
C to r.t, 40.1%  (b) mCPBA (1 
equiv), K2HPO4 (1 equiv.), CH2Cl2, 0 
o
C, 20 h, 88.9% 
 
 
Scheme 10: Synthesis o 1,4-cyclohexadiene and 1,4-cyclohexadiene monoxide 
 
 
5.2  Enantioselective epoxide ring opening 
 
 
Organic azides are an important class of compounds, particulary for producing primary 
amines. Moreover, they are involved in many synthetic reactions such as “clicked” 
reactions
12a
, intramolecular cycloadditions of nitrenes
12b
, Staudinger reductions
12c
, 
Curtius rearrangement
12d
 and many more. Jacobsen et al. reported in 1995, the 
asymmetric ring-opening (ARO) of epoxide 67  catalyzed by (salen)Cr(III) complex 70 
giving the corresponding azido silyl ether 66 in 72% and 81% ee.
13
  
Following this protocol, the enantioselective asymmetric ring opening of the epoxide 67 
using Salen catalyst complex 70 with trimethylsilylazide furnished the azido  
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trimethylsiloxy cyclohexene in 68% and 86% ee as depicted in Scheme 11. Jacobsen 
rationalized this transformation by the formation of a chromium-azide coordinated 
species as the active catalyst
13a,b
 which could be driving the enantioselection of this 
process, affording the preferred trans- azido silyl ether 66 (Scheme 12). The 
corresponding racemic azido silyl ether was also synthesized.  
O
OTMS
N3
N N
t-Bu
t-Bu t-Bu
O O
Cr
Cl t-Bu
67
70
66  
Reagent and conditions: (a) Salen complex (2 mol%), TMSN3 (1.05 equiv.), Et2O, rt, 46 
h, 68%, 86% ee 
Scheme 11: Epoxide ring opening by salen complex 
 
 
 
 
Scheme 12: Epoxide activation by (salen)Cr(III) complex 
N
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5.3      Reductive amination and Boc protection of 66 
In principle, the tert-butoxy carbonyl protecting group can be easily and quantitatively 
introduced under mild conditions. Facile cleavage of this protecting group by TFA in 
DCM or concentrated HCl in ethyl acetate is a useful criteria for application in peptide 
synthesis. The combination of azide reduction and N-Boc protection in a one-pot 
reaction, offers an efficient approach for the synthesis of suitably protected amino acid. 
In  1997, Katsuki et al. developed a facile method for the chemoselective reductive 
transformation of several azides 71 and 73 to N-(tert-butoxycarbonyl) amines 72 and 
74.
14a,b
 Some examples of this transformation are tabulated in Table 1.  
Table 1: Some examples of reductive amination 
 
Entry Reaction
1.
OH
N3
Boc2O (1.5 equiv)
Et3SiH (1.5 equiv)
20% Pd(OH)2/C
EtOH
76%
OH
NHBoc
2. EtOOC
N3
OBn
Boc2O (1.5 equiv)
Et3SiH (1.5 equiv)
20% Pd(OH)2/C
EtOH
84%
EtOOC
NHBoc
OBn
71
72
73 74
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By applying the same procedure, azide reduction and in situ amine protection of azido 
trimethylsiloxy cyclohexene 66 with Pd(OH)2/C and di-tert-butyl dicarbonate (Boc 
anhydride) as trapping agent in ethanol and followed by addition of with triethylsilane as 
proton donors gave 65 in 88% yield as depicted in Scheme 13.  
OTMS
N
H
O
O
a
OTMS
N3
66 65  
Reagent and condition: Boc2O (1.5 equiv), Pd(OH)2/C, Et3SiH (1.5 equiv.), EtOH, r.t, 
20 hrs, 88% 
Scheme 13: Reduction amination and Boc protection 
 
5.4 Oxidation of double bond by ozonolysis and lactonisation 
 
The protected amine 65 was subjected to ozonolysis at –78 °C followed by reductive 
workup with DMS at room temperature for 20 h to give dialdehyde 64 in 62% yield. The 
dialdehyde 64 was then transformed to the corresponding carboxylic acid  using Jones’ 
reagent in which dicarboxylic acid spontaneously undergoes lactonization to give the (-)-
63a lactone lactam in 59% yield. When dialdehyde 64 was oxidized with sodium chlorite 
in the presence of hydrogen peroxide and potassium dihydrogen phosphate in acetonitrile, 
the (-) lacton lactam 63a was only obtained in 23% yield (Scheme 14). 
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CH3
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CH3
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OHC
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O
O
CH3
CH3
CH3
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65 64 63a
OO
Boc
N
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Reagent and condition : (a) O3, DMS, CH2Cl2, -78 
o
C to rt, 20 h, 62% (b) Jones reagent, 
AcOH, 10 
o
C, 15 min, 59%  (c) i. NaClO2 (0.6 equiv), KH2PO4 (0.6 equiv), 30% H2O2 
(1.6 equiv), CH3CN, 3 h, 0 
o
C, ii. Na2SO3, 2 h, 0 
o
C. iii. KHSO4, pH2, 23% 
Scheme 14: Synthesis of (-) lactone lactam 
 
5.5      Ruthenium catalyzed oxidative cleavage of double bond in 65 
 
Ruthenium tetraoxide (RuO4) has been used mainly as a strong oxidizing agent for 
alcohol
15
, aldehydes
15a
, alkenes
16
 and alkynes
17
. Being less toxic and less volatile than 
OsO4, RuO4 has been used also as catalyst for selective dihydroxylation of olefins
18
 and 
for cleavage reactions
19
. RuO4 can be generated from RuCl3 or RuO2 in the presence of 
an appropriate oxidant, such NaIO4, NaOCl, NaBrO3, Oxone, O3, Ce(SO4)2 and K2S2O8 
20
. 
 
Applying RuO4 it was envisioned to cleave the double bond in 65 directly to give rise to 
the dicarboxylic acid 63b and to obtain the requisite lactone lactam 63a via lactonization. 
Lactonization is an intramolecular cyclization to form five membered ring units. The 
double bond cleavage is accompanied by the deprotection of trimethylsilyl (TMS) group  
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since ruthenium tetraoxide can behave as a weak acid as suggested by Martin  in 1954 as 
show in equation   below:
21 
 
 
RuO4 + H2O H2RuO5
H2RuO5 + H2O H3O
+
+ HRuO5  
    
 Treatment of 65 with ruthenium tetraoxide and sodium periodate gave spontaneously rise 
to 63a. We postulate that once the lactone is formed, ring closure is facilitated by the 
formation of hydrogen bonding from migrating hydrogen atom to the hydroxyl 
functionality. Nucleophilic attack of the nitrogen lone pair onto the carbonyl group 
afforded lactone 63a. The structure was confirmed by X-ray crystallographic analysis. 
 
OTMS
N
H
OO
N O
O O
63a
O
O
a
65
 
Reagent and condition: RuCl3.3H2O (8.3 %mol), 
NaIO4 (4.1equiv.), CCl4:CH3CN, H2O (1:1:2), 0 
o
C, 62% 
Scheme 15: Synthesis of (-)-lactone lactam 63a by ruthenium catalyzed oxidative 
cleavage 
 
Type a quote from the 
document or the summary of an 
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the formatting of the pull quote 
text box.] 
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Scheme 16: Proposed mechanism of lactonization after oxidative cleavage by ruthenium 
tetraoxide 
 
6.0 Synthesis towards (-)-GWL 
6.1 Retrosynthesis towards (-)-GWL 36b 
The (-)-GWL 36b can be envisioned from N-protected GWL 75, by removing the N-Boc 
group. Compound 75, can then be derived by chemoselective reduction of the lactam 
carbonyl group of 63a as depicted in Scheme 17. 
 
 
 
OO
N O
O O
O
O
N
O O
OO
H2Cl
N
36b 75 63a  
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Scheme 17: Retrosynthetic analysis to (-)-GWL 36b 
 
6.2 Synthetic outline towards (-)-GWL 
6.2.1 Selective reduction of carbonyl group and deprotection 
In an effort towards the synthesis of (-)-GWL 36b, the next step is to reduce the lactam of 
63a to arrive at 36b. Several methodologies for the chemoselective reduction of lactams 
to pyrrolidines in the presence of lactone, have been developed. In 2004, Huang et al 
reported that the chemoselective deoxygenation
22
 reduction of 76 could be achieved by 
treating 76 with three equivalent of borane dimethylsulfide in THF at room temperature 
for 24 hours to give lactone 77 in 58% and the fully reduced 78 in 10% yield (Scheme 
18). 
 
 
 
Scheme 18: Chemoselective reduction of carbonyl lactam with boron dimethylsulfide 
 
Selective reduction of carbonyl group near to amide functionality of (-)-lactone lactam 
63a by borane dimethylsulfide gave 75 in 53% yield. Analysis of the product by HPLC  
O
N
PMB
O
O
H3B-SMe2  (3 equiv.)
THF, 24 h
O
N
PMB
O
+
O
N
PMB
42 43 76a  
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showed only a single peak with retention time at 25 min indicating that its stereoisomeric 
purity. Subsequent deprotection of the latter compound by hydrogenation furnished 
exclusively the cis (-)-Gaissman Waiss Lactone (Scheme 19). 
OO
N O
O O
OO
N
O O
OO
H2Cl
N
+
O
N
O O
63a 75 76b
36b
a
b
 
Reagent and condition: : a. H3B-SMe2 (3.0 equiv.), THF, 24 h, (75 : 53% ; 76b : 11%).  
b. HCl / EtOAc: quant.  
Scheme 19: Synthesis of cis (-)-Gaissman Waiss Lactone 
 
 
 
 
 
 
 
HPLC condition: Chiral column OD, 215+254 nm, solvent system 
20% isopropanol in heptane, flow rate: 1 ml/min  
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7.0 Conclusion 
The synthesis of (-)-GWL from benzene disclosed here is an easy and short route, but low 
overall yield was achieved (13%) for the synthesis of key intermediate lactone lactam 
63a from benzene compared to 34% overall yield synthesized from N-protected amino 
acid developed by Jouin et al.
10 
Nevertheless this approach differs from others known  
strategy, since compound 63a can be used as a versatile intermediate especially for 
synthesizing more complex medicinally important compounds such as Tiagabine 77 
(GABA transporter), a building block for anti Hepatitis C 78 and fluoroquinolone 79 for 
anti bacteria (Figure 6b).  
N
H
OH
OH
O
HCl.
N
HR
N
O
COOH
N
H
COOH
R
OH
77 78 79  
Figure 6b: Medicinally important compounds 
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C. Enantioselective synthesis of functionalized cis -
butyrolactone derivatives.  
 
1. Introduction 
-Butyrolactone, a five membered ring lactone, has served a pivotal role as an interesting 
synthon in the design and construction of a variety of biologically active natural product 
compounds based on natural occurring substances.
1a
 Thus employing butyrolactone 
moiety in the design and construction of new natural products, significantly contributes to 
the enrichment of existing pool of known biologically active substances.  
Many functionalized -butyrolactone have been identified as versatile intermediates for 
synthesizing complex medicinally important compounds such as ionomycin, lasalocid A, 
elaiophylin, calcimycin, carbapenam alkaloids,
1a
 ellipticine,
1b
 (+)- grandisol,
1c
 
bacilosarcin B 
1d
 and many more.  
The above compounds with the basic -butyrolactone scaffold have received much 
attention due to their diverse medicinal properties such as antibiotic, antitumor, 
antifungus, pheromone, etc. Some of the corresponding molecular structure and 
biological activity of compounds containing -butyrolactone scaffold are tabulated in 
Table 2. 
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Table 2: Molecular structure and biological activity of  compounds containing -
butyrolactone scaffold 
 
Name  Molecular Structure Biological activities 
 
(-) Muricatacin 
  
Antitumor
1e
 
 
11-
Deoxyprostaglandins 
 
 Anti-inflammatory, anti-
apoptotic, anti 
asmthmatic agents 
 
Eldanolide 
 
  
Phermone 
 
(+) Blastmycinone 
  
 
Antifungal agents 
 
Pilocarpine 
 
 
Commonly used in the 
treatment of glaucoma.
1f
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(-)-Methylenolactocin 
 
 
Antitumor, antibiotic 
 
(-)Aplysistatin 
 
 
Anti-neoplastic agent 
 
(-) Vertinolide 
 
 
Antibiotic, insecticidal, 
herbicidal 
1g, 1h
 
 
Based on their notable therapeutic properties, the design and synthesis of -butyrolactone 
analogs should undoubtedly lead to the development of novel pharmaceutical agents. 
 
2. Synthesis of -Butyrolactone 
Several stereoselective approaches towards the synthesis of (+) or (-)--butyrolactone 
have been published. Taniguchi et al. reported the synthesis of (+)--butyrolactone from 
L-glutamic acid.
2
 The requisite (+)--butyrolactone was prepared in three steps as  
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depicted in Scheme 20. Glutamic acid 80 was converted to - carboxylic-butyrolactone 
81 by deamination in aqueous nitrous acid. Subsequent esterification in ethanol, followed 
by reduction with NaBH4, giving rise to (+)--butyrolactone 83 in 65%. 
HO
NH2
H COOH
O
NaNO2
O
COOHO
PhH
O
COOEtO
OO
OH
H2/HCl
EtOH/ TsOH
NaBH4/ EtOH
65%
80 81 82
83  
Scheme 20: Synthesis of (+)--butyrolactone developed by Taniguchi and coworkers 
Camps et al described an efficient transformation of D-ribonolactone 84 into (+)--
butyrolactone as depicted in Scheme 21.
3
 According to Camps, protection of dihydroxyl 
group of D- ribonolactone  84 by HC(OEt)3  to give cyclic orthoformate 85, which was 
converted into butenolide 86, by pyrolysis. Hydrogenation of the enone afforded (+)--
butyrolactone 87. 
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Scheme 21: Synthesis of (+)--butyrolactone developed by  Camps and coworkers 
Ghosal et al showed (+)--butyrolactone 4, could be derived from commercially available 
and inexpensive D-ribose as depicted in Scheme 22. In this route, Ghosal claimed that an 
appropriate precursor or key intermediate, butenolide could be accessible through D-
ribose 88 in five steps. Protection and methylation of D- ribose 88 followed by iodination 
of 89 gives 90. Applying Boord reaction or alkoxy-halo elimination of 90 gave aldehyde 
91. Treating the corresponding aldehyde 91 with phosphine ester through Wittig reaction, 
followed by deprotection and hydrolysis of methyl group gave the butenolide 92. By 
applying RCM methodology on the latter, followed by hydrogenation could afforded (+)-
-butyrolactone 93. 
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Scheme 22: Synthesis of (+)--butyrolactone developed by  Ghosal and coworkers 
3. Synthesis of  β- Substituted -Butyrolactone 
In the forward sense, functionalized (+)--butyrolactone have served as key building 
blocks in the synthesis of many types of natural products. Much researched has been 
performed to functionalize (+)--butyrolactone, especially at the β- position. Toshiyuki 
and co-workers reported a new approach towards the synthesis of β-substituted -
butyrolactone, ie (+) eldanolide via intramolecular radical cyclization methodology ad 
depicted in Scheme 23.
5
  They showed that  (+)-eldanolide 96, could be derived from 
butyl acetal  95, which could be in turn be prepared from allyl alcohol 94.  
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OH
NBS
O
Br
O
OOButyl vinyl ether
i. nBu3SnH, AIBN
ii. Jones Oxidation
94 95 96
 
Scheme 23: Synthesis of β-hydroxy -butyrolactone developed Toshiyuki and co-
workers 
Takahata et al discovered a new method to functionalized (+)--butyrolactone, at β- 
position through iodolactonation of homo chiral N-benzyl-N-methyl-3-hydroxy-4-
pentenamide as depicted in Scheme 24.
6
 In this route, Takahata claimed that an 
appropriate precursor of β- substituted -butyrolactone could be accessible through 
intramolecular iodolactonization of 97 to provide directly lactone 98, with high 
diastereoselectivity (8:1 = cis:trans) ratio due to direction by an allylic hydroxyl. 
Compound 98 could be transformed into β-hydroxy -butyrolactone 101 via cross 
coupling with Grignard derived cuprates, followed by elimination with ammonia in 
methanol to give butenolide 100. In addition, the conjugate addition of 
tris(phenylthio)methyllithium and quenching with methyl iodide  gave the ,β-substituted 
-butyrolactone 101. 
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OO
R
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Scheme 24: Synthesis of β-hydroxy -butyrolactone and ,β-substituted -butyrolactone 
developed Takahata and coworkers 
 
In the synthesis of biologically active aquatic natural peptide for example micro-
sclerodermins has attract much attention because of their potent towards anti-fungal and 
anti proliferative activities. One of the requisite building blocks to synthesize the 
compound is a -butyrolactone moiety. Takayuki et. al. synthesized this amino acid in 
three steps from N- Boc (S) - aspartic acid 4 - benzyl ester 102.  Takayuki showed that 
homologation of the later with 1,1-carbonyldiimidazole (CDI)  to  give β- keto ester 103, 
which was transformed to dicarboxylic acid 104. Lactonization of 104 with EDC gave β 
–substituted -butyrolactone acid 105.7 
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Scheme 25: Synthesis of β,-butyrolactone amino acid 
 
 
Masaru
1d
 described the synthesis of β-substituted -butyrolactone starting from aldehyde 
106 as depicted in Scheme 26. Asymmetric epoxidation of aldehyde 106 under the 
organocatalytic condition proceeded smoothly to give epoxy 107. Subsequent chain 
elongation through Wittig reaction afforded  epoxy- ,β-unsaturated ester 108, which 
could be transformed into hydroxy lactone 109 by intramolecular epoxide ring opening 
reaction after treatment with TFA. Then subsequent  conjugate addition of 109 with 
sodium azide gave the corresponding  β-azido -butyrolactone 110. 
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Scheme 26: Synthesis of  β-azido,-butyrolactone ester 
 
Mahbbobul et al. used furan-2-carboxylic methyl ester 2  to synthesized trans--
butyrolactone amino acid (Scheme 27).  The copper (I) bis(oxazoline)-catalysed 
asymmetric cyclopropanation
8
 afforded 112, which was recrystalized from pentane in 
>99% ee.  Ozonolysis of 117 followed by reductive workup led to aldehyde 113 in 
diastero- and enatiomerically pure form.  Boron trifluoride mediated addition of 
allyltrimethylsilane yielded 114 as a 95 : 5 diastereomeric mixture, which was used for 
further reaction without purification, directly transformed on a retro-aldol/lactonization 
cascades under basic condition to generate lactone 115. The aldehyde functionality of 
115 was oxidized to the corresponding acid 116 followed by Curtius rearrangement  of 
the latter by diphenylphosphoryl azide (DPPA) to give carbamate 117. Oxidative 
cleavage of the allylic double bond of 117 furnished  - amino acid 118. 
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OC(O)E
OHC
H
CO2Et
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OC(O)E
H
CO2Et
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H
EtO2C
H
N
OO
N
Pr
i i
Pr
OO
CO2H
OO
CO2H
NHBoc
OO
NHBoc
OO
CHO
113112
E = CO2Me
b
114
111
a c
95 : 5
d
116
f
117 118
e
Ligand
115
bis-oxazolin
g
Reagent and condition :  (a) (i) ethyl diazoacetate (1.6 equiv), Cu(OTf)2 (0.66 mol%),  
(-)-10 (0.83 mol%), PhNHNH2 (0.83 mol%), CH2Cl2, 95% ee; (ii) recrystallization 
(pentane), >99% ee, 53%.  (b) (i) O3, CH2Cl2, -78 
o
C; (ii) dimethyl sulfide, 94%.  (c) (i) 
BF3
.
OEt2, -78 
o
C; (ii) allyltrimethylsilane.  (d) Ba(OH)2
.
8H2O, MeOH, 0 
o
C, 64%. (e) 
NaClO2 (1.6 equiv), H2O2 (1.6 equiv), KH2PO4 (0.6 equiv), CH3CN-H2O, 0 
o
C, 87%. (f) 
DPPA (1.1 equiv), Et3N (1.1 equiv), 
t
BuOH, reflux, 20 h, 52%. (g) RuCl3
.
3H2O (6.3 
mol%), NaIO4 (4.0 equiv), CCl4-CH3CN-H2O (1 : 1 : 2), 0 
o
C, 42 h, 79%. 
Scheme 27: Synthesis of  trans -butyrolactone amino acid 
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4. Synthesis of cis -butyrolactone amino esters 
4.1 Retrosynthetic analysis of N-Boc protected  cis -butyrolactone amino ester 
N-Boc protected cis -butyrolactone amino ester 119 can be envisioned from azido 
trimethylsiloxy cyclohexene 66.   Oxidative cleavage of 66 by ruthenium tetraoxide 
catalysis give azido carboxylic acid 121, benzyl protection at carboxyl functionality, 
reduction amination of azide to amide followed by in situ protection of the amine group 
should afford 119. 
OTMS
N3
OO
N3
O
OHO
O
NHBoc
O
O OO
N3
O
O
66
119 120 121
Scheme 28: Retrosynthetic strategy of N-Boc protected  cis -butyrolactone amino ester 
 
4.2  Synthesis of N-Boc protected cis -butyrolactone amino ester 
4.2.1   Oxidative cleavage by ruthenium 
 
Azido trimethylsiloxy cyclohexene 66 undergoes lactonisation by ruthenium tetraoxide in 
the presence of sodium periodate
9
 through intermediate 122 to give the corresponding 
azido carboxylic acid 121 in 62% as depicted in Scheme 29. 
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OTMS
N3
OO
N3 O
OHa
66
121
OH
N3
O
HO
O
HO
122  
Reagent and condition : d) RuCl3.3H2O (8.3 %mol), NaIO4 (4.1equiv.), CCl4:CH3CN, 
H2O (1:1:2), 0 
o
C, 62% 
Scheme 29: Synthesis of azido acid 121 
4.3  Determination the purity of azido acid 121 by coupling with chiral amine 
The purity of azido acid 121 was determined by coupling the carboxyl group of azido 
acid with (R)-phenylethanamine
10
 to give dipeptide 123 (Scheme 30). Analysis of the 
crude product by HPLC showed only single peak at retention time 31 min indicating that 
a single enantiomer was produced during the lactonization. So we assume that the azido 
acid 121 purity is more than 99% (Figure 7). The corresponding racemic dipeptide was 
also synthesized for comparison. Ebata T et al. synthesized cis - lactonic carboxylic acid 
from (1S,2S) 1-benzoyloxy-2-methyl-4-cyclohexene 124. Oxidative cleavage using 
ruthenium oxide in the presence of sodium periodate in biphasic solution of CCl4, MeCN 
and water gave the corresponding dicarboxylic acid 125. Subsequent lactonization with 
concentrated acid furnished cis -- lactonic carboxylic acid11 126 (Scheme 31).  
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a
 
Reagent and condition : (a) (R)-phenylethylamine (1.1 equiv.), HOBt (1.1 equiv.), 
HBTU (1.3 equiv.), THF, 48% 
Scheme 30: Coupling reaction of azido acid 121 with chiral amine 
 
 
Figure 7:  HPLC spectrum for dipeptide 123 and racemic dipeptide 
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Scheme 31: The synthesis of cis - lactonic carboxylic acid from (1S,2S) 1-benzoyloxy-
2-methyl-4-cyclohexene developed by Ebata et al. 
 
4.4  Synthesis of -butyrolactone ester derivatives   
 
Benzylic protection
12 
of carboxylic acid 121 gave ester 120. This was accomplished by 
treatment with benzyl bromide together with side product 127 due to azide elimination 
(Scheme 32). Compound 127 could be used as an intermediate compound to synthesize 
micromolide which showed good in vitro anti-TB activity (MIC: 1.5 μg/mL)13.   In 
addition, esterification of 121 with diazomethane to give ester 128 also was performed in 
good yield (89%). 
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Reagent and condition : (a)  BnBr (1.6 equiv.), NaHCO3 (6 equiv.), DMF, 43 h, rt. 69% 
b. CH2N2 (excess), Et2O, 89% 
Scheme 32: Synthesis of -butyrolactone ester  
By using different bases in the reaction, different product yields could be obtained. For 
instance, a strong base, potassium carbonate could afford more elimination product as 
depicted in Table 3.  
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Table 3: Effect of base in esterification of azido acid 121 
OO
N3 O
OH O
O
N3 O
O OO
O
OBnBr, DMF +
127120121
RT. 20 h
Entry Base
1
2
triethylamine
K2CO3
Yield (%)
40 20
6 60
 
By allowing this transformation strategy to take place, a wide range of cis -
butyrolactone ester derivatives could be synthesized as depicted in Table 4.  
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Table 4: cis-Butyrolactone ester derivatives and butenolide: their antituberculosis 
cytotoxicity activity. 
O
O
N3
OH
O
O
O
N3
OR
O
+
O
O OR
O
R Br
R
O
FF
F
CN
NO2
O
O
-CH(CH 3)2
46.9 22.7
49.5
48.4
47.9 45.5
49.9 43.7
>100 >100
11.1 8.4
DMF, NaHCO3
3
4
5
6
MIC(g/ml)
1
OO
N3
O
O
OO O
O
OO
N3
O
O
O F
F
F
OO O
O
O F
F
F
R OH or
OO
N3
O
O
CN
OO O
O
CN
OO
N3
O
O
NO2
OO O
O
NO2
O
O
N3
O
O
O
O
O
O O
O
O
O
OO
N3
O
O
OO O
O
120
129 130
131 132
127
133 134
135 136
137 138
MIC(g/ml)
b
Entry
2
IC50 (ug/ml)
a IC50 (ug/ml)
>20 (0%) >20 (0%)
79.51 90.37
>100 (41%)
83.3
79.62 94.32
79.62 94.32
- -
a: antituberculosis activity value     b: cytotoxicity value
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In this study, we wanted to test whether our synthesized compounds have anti-TB 
abilities. Therefore, thirteen of the synthesized compounds were chosen and tested to 
determine their ability to inhibit H37Rv Mycobacterium tuberculosis strain.  
 
In this biological study, the inhibitory activity of compounds against M. tuberculosis 
were evaluated by the MABA (microplate Almar Blue assay) method.  MABA is 
sensitive, rapid, inexpensive and non-radiometric method which is able to screen a large 
number of antimicrobial compounds against slow-growing mycobacteria. The Alamar 
blue reagent, an oxidation-reduction dye is a general indicator of cellular growth and 
viability. After reduction, the blue which is non-fluorescent and the oxidized form  
becomes pink and fluorescent. Growth can be analyzed using a fluorimeter or 
spectrophotometer or determined by a visual color change. The minimum inhibitory 
concentration (MIC) is defined as the lowest drug concentration effecting growth 
inhibition of >90% relative to the growth for the drug-free control. 
 
The MIC values using the MABA assay for these compounds are presented in Table 4. 
In general, the azido cis -butyrolactone ester analogs are less active than their 
corresponding butenolide benzyl ester analogs. Compound 120, without any substituent 
on the benzyl ring showed the high activity (MIC= 11.1 g/ml). This data suggest that in 
the presence of electron withdrawing group (EWG) at meta position (compound 129) or 
para position (compound 131, 133) and electron donating group (compound 135) on the 
benzyl ring results in reduced activity., while no significant activity was observed  for the 
branched isopropyl group ( compound 137). 
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According to Table 4, most of the butenolide benzyl esters showed considerably reduced 
activity except for butenolide 127 which shows higher MIC value (8.4 g/ml) and 130 
with 22.7 g/ml MIC value.  
In conclusion, compounds 120 and 127 tested for antituberculosis activity and were 
determined to be non-toxic on mammalian cell line (IC50 >20 (0%)). 
 
 
4.5 Synthesis of cis -N-Boc butyrolactone derivatives and cis -butyrolactone 
amino acid 
Reductive transformation of the azide 120 or 128 was performed using Boc2O in the 
presence of Pd(OH)2/C and triethyl silane as proton donor which yielded the N- (tert- 
butoxycarbonyl) amino lactone 139 or 140. Deprotection of benzylic group in 139 by 
Pd/C   afforded amino acid 141 (Scheme 33). 
O
O
N3 O
OR
OO
R2
N O
OR1
H
    R2 : Boc
R2
    R2 : Boc
120   R : Bn
128    R : Me
139
140   R1 : Me : Boc
141
a,b,c
139a R1 : Bn R2 : TFA
R1 : H
R1 : Bn
 
 
Reagent and condition : (a) Boc2O (1.5 equiv), Pd(OH)2/C, Et3SiH (1.5 equiv.), EtOH, 
r.t, 20 h, (139: 71% %) (140:74 %) (b) TFA, DCM, quant. (c) a. Pd/C, H2, MeOH, 84 % 
Scheme 33: cis -N-Boc butyrolactone derivatives 
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5. Synthesis of cyanotrimethyl silane 
Cyanotrimethyl silane derived from asymmetric ring opening (ARO) of meso epoxide 
with TMSCN and catalyzed by chiral complexes ligand, can be used as a synton to 
synthesize novel cis amino acids. Jacobsen et al reported the possibility of effecting 
cyanide ARO  reaction with lanthanide- base catalyst.
14
 They found that (pybox)YbCl3, 
effectively promote the ring opening of epoxide 142 to yield cyanotrimethyl silane 143  
as tabulated in Table 5 (entry 1). Kagan et al. reported that lanthanide chloride salts also 
promote ARO of epoxide 144 with TMSCN in good yield to give cyanotrimethyl silane 
145 adduct but no selectivity (Table 5, entry 2)  
Table 5: Asymmetric ring opening (ARO) of meso epoxide with TMSCN and catalyzed 
by chiral complexes ligand 
 
Entry                     Reaction                                     Ligand                  yield (%)        ee (%) 
 
O
OTMS
CN
N
N
OO
N
OH3C
CN
OTMS
H3C
1
10 mol% YbCl3
12 mol% ligand
TMSCN (1.2 equiv.)
CHCl3
(S,S)-Ph-pybox
2
10 mol% MCl3
TMSCN, DCM
M = Sm, Ce, La
+
_
90 91
(1S, 2R)
racemic
Sm = 88
Ce  = 85
La  = 77
142 143
144 145
racemic
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Inspired by the above discovery, we conducted several screening ARO of racemic 
epoxide 67 with TMSCN catalyzed by (pybox)YbCl3 or (pybox)YbCl3.6H2O to give 
cyanotrimethyl silane 146 as tabulated in Table 6). 
Table 6: ARO of racemic epoxide 67 with TMSCN catalyzed by (pybox)YbCl3 or 
(pybox)YbCl3.6H2O 
O
OTMS
CN
Ligand, TMSCN
 (1.5 equiv.)
Lewis acid
DCE
67 146  
 
Entry   (S,S)-ph-pybox         Lewis acid               Conditions      Yield %
a
   20D    ee (%)
b
 
 
    
1                    -                 5 mol% YbCl3. 6H2O        reflux, 5 h     65          0         0  
 
2            10 mol%            5 mol% YbCl3.6H2O         reflux, 5 h     69        -5         3 
 
3            12 mol%            5 mol% YbCl3.6H2O         reflux, 5 h     54        -9         4  
 
4             10 mol%           12 mol% YbCl3.6H2O       0
o
C, 4 d        23         -3        0 
 
5                  -                   YbCl3                                 RT, 24 h       65          0         0 
 
6            10 mol%            12 mol% YbCl3                 reflux, 5 h     40         -14     10 
 
7            10 mol%            12 mol% YbCl3                reflux, 24 h    75         -6        3 
 
8            10 mol%            12 mol% YbCl3                reflux,  4 d     52          -8       4 
 
 
 
 
a
 isolated yield, 
b
 determined by chiral GC 
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ARO of cyclohexene oxide with TMSCN in DCE and catalyzed by chiral (pybox)YbCl3 
complexes or  (pybox)YbCl3.6H2O did not show good enantioselectivity. Only entry 6 
gave highest enantioselectivity, ie 10%. However in this reaction, by employing 10 mol% 
(S,S)-ph-pybox and  12 mol% YbCl3, the decrease in yield was observed. By lowering the 
reaction temperature to 0
o
C or increase the lewis acid, did not help to improve the 
enantioselectivity. When the reaction was carried out in DCM or THF, the product was 
not observed. 
 
6. Conclusion 
In summary, a convenient and facile strategy for the synthesis of enantiopure azido acid  
bearing -butyrolactone scaffold 121, was developed. Several cis -butyrolactone ester 
derivatives and their corresponding butenolide ester were synthesized. Some of them 
exhibited good in vitro anti-tuberculosis (TB) activity. This results open furthermore the 
possibility to design a new anti-TB compounds based on cis -butyrolactone scaffold. 
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D. Synthesis of peptides from sugar amino acid 
 
1. Introduction 
Sugar amino acid (SAAs) is grouped into one of the glycosamino acids. The carboxylic 
acid and amino functionality are incorporated directly into a cyclic five or six membered 
ring of a carbohydrate skeleton, which produces restrict conformation.
1
 General structure 
of SAAs is depicted in Figure 7. 
   
X
n
COOH
H2N
OH
X = O, S, P
n = 0,1,2,...  
Figure 7: General structure of SAAs 
The rigidity of SAAs is an important factor to generate secondary structure in oligomers 
or short peptides. Several SAAs have served as building blocks for the synthesis of 
furanoside- based antisence oligonucleotides 147 and 148 as depicted in Figure 8.
2
 
 
O
N3
HOOC OTBDMS
H
N
N
O O
O
NHBoc
H
N
N
O O
COOH
147 148  
Figure 8: Examples of building blocks used in the synthesis of furanoside- based 
antisence oligonucleotides 
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SAAs 149, adopt a secondary structure ie, mimic   and -turn when incorporated into a 
short peptide sequence.
3
 
   
O
OH
COOH
OH
OH
NH2
149  
Due to its ability to form restricted conformation in peptides, SAAs have been used as 
oligosaccharide mimics. In 1996, Ichikawa et al reported the first characterized 
carbopeptides by using D-glucoseamine- derived SAAs building block 149 as a key 
building block
4
 as depicted in Scheme 34. Elongation of 149, afforded the tetramer 150, 
in which after O-sulfation showed a strong inhibitory potency against HIV infection of 
CD4 cell.  
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O
OH
COOH
OH
OH
NH2
O
OH
OH
OH
NHBoc
OC NH
O
OH
OH
OH
OC NH
O
OH
OH
OH
OC NH
O
OH
OH
OH
OC NH
H3COOC
149
150  
Scheme 34: Carbopeptides synthesized from D-glucoseamine- derived SAAs building 
block 
Over the last two decades, there have been dramatic increase in the field of 
peptidomimetic, in which SAAs is oligomerized into other amino acid. Kessler and co-
workers were the first to demonstrate the potential of SAAs as peptidomimetics.
5 
They 
claimed that, the Pro-Phe dipeptide sequence in the somatostatine analog cyclo (Pro-Phe-
D- Trp-Lys-Thr-Phe)  151, was replaced  by the dipeptide isosteres 152 to give the potent 
hexapeptide mimetic somatostatine analog 153 as depicted in Figure 9. Somatostatine is a 
14-residue cyclic peptide hormone formed in the hypothalamus, which plays an important 
role in a lots number of physiological actions, for instance, it inhibits the release of 
growth hormone,
6
 insulin secretion
7
, tumor cells and it induces apoptosis.
8
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HO
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151 152 153
                                                                                                                                                                
Figure 9: Hexapeptide mimetic somatostatine analog synthesized by Kessler et al 
The same group was also able to manipulate the cyclic pentapeptide cyclo (Arg-Gly-Asp-
D-Phe-Val)   structure. This cyclic pentapeptide binds selectively to the v3 receptor of 
the integrin family. They incorporate the SAAs 152 analog into cyclic peptides that 
contain RGD (Arg-Gly-Asp) motif. Replacement of D-Phe-Val sequence with isostere 
152 analog furnished the potent peptidomimetic 154 with high v3 receptor activity 
(IC50 = 25 nM)
9
 as depicted in Figure 10. 
O
OBn
OBnBnO
O
HN
H
N
NH2
+
NH2
O
NH
O
NH
HOOC
O
NH
154  
Figure 10: Peptidomimetic RGD analog synthesized by Kessler et al 
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On the other hand, Chakraborty and co-worker, incorporated the furanoid SAAs 155, into 
Leu-enkephalin sequence 156.
10
 Replacement of the Gly-Gly sequence in Leu-
enkephalins 156 by the isosteres 155 afforded the biologically active peptide 157 as 
depicted in Figure 11. 
+H3N
HO
O
H
N
O
N
H
H
N
O
N
H
O
O
-
O
+H3N
HO
O
H
N
H
N
O
N
H
O
O
-
O
O
OH
HO
COOHH2N
O
OHHO
155 156
157   
Figure 11: Peptidomimetic Leu-enkephalins analog synthesized by Chakraborty et al 
2. Synthesis of - Sugar Amino Acids 
Fleet et al reported the synthesis of - SAAs as depicted in Scheme 35.  They used 
monosaccharides which commercially available, as the starting material.
11
 
They converted 158, into their corresponding azide 159 by addition of catalytic amount 
of Bu4NCl.
12
 Subsequent deprotection of the exocyclic hydroxyl 159 with acetic acid  
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yielded diol 160. Azide reduction of the latter and Fmoc protection in one pot reaction, 
gave rise to N-Fmoc diol 161, which was then converted to the desired - SAAs 162 after 
primary alcohol oxidation mediated by TEMPO. 
 
O
O
O
O
O
1. Tf2O, py
2. NaN3, Bu4NCl (cat.)
69%
OH
O
O
O
O
O
N3
77% HOAc
quant.
O
O
O
N3
CH2OH
HO
1. H2, Pd/C
2. FmocCl, NaHCO3
90%
O
O
O
NH
CH2OH
HO
Fmoc
NaOCl, TEMPO (cat.)
KBr, NaHCO3
Bu4NCl
62%
O
O
O
NH
HO
Fmoc
O
HO
158 159 160
161 162
 
Scheme 35: Synthesis of Fmoc-Protected SAAs developed by Fleet et al. 
 
3. Synthesis of Homooligomer 
SAAs have also served as candidates for biopolymer scaffolds to mimic oligosaccharide 
and polysaccharides structure. Several research groups have developed libraries of 
oligomers based on SAAs monomers. Fleet et al reported the syntheses of tetramer 171 
and octamer 172 from carbohydrate-like tetrahydrofuran 163 as building blocks. This  
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monomer could be envisioned from commercially available D-glucono- 1,4- lactone.
13
  
They claimed that tetramer 171 exhibits no conformational preferences (no secondary 
structure) whereas the octamer 172 exhibits a well- defined left handed-helical 
conformation stabilized by hydrogen bonding. In their route, the isopropyl ester, D-talo 
163 was transformed into the corresponding acid 164 after ester hydrolysis by aqueous 
NaOH. The azide group in  D-talo 164 was reduced into the corresponding amine 165 by 
hydrogenation in the presence of Pd/C. The acid 164 and amine 165 were coupled to give 
dimer 166. From dimer 166, tetramer 169 and octamer 172 were synthesized by applying 
the same methodology as depicted in Scheme 36.  
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O
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55%
 
Reagent and conditions: a) 0.5 M NaOH (aq), dioxane; Amberlite IR 120 (H
+
). b) H2, 
Pd/C. c) EDC, HOBt, (
i
pr)2Net, CH2Cl2  
Scheme 36: Carbohydrate-like tetrahydrofuran homooligomers by Fleet et al 
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4.        Retrosynthesis strategy of tetrapeptide 173 using solution phase procedure 
In an effort to synthesize tetrapeptide 173, we decided to carry out the synthesis in 
solution phase rather than in a solid phase synthesis protocol. Tetrapeptide 173 was 
envisioned to be synthesized in solution from azido carboxylic acid 121 via an iterative 
peptide coupling procedure as depicted in Scheme 37. 
OO
NHBoc
O
N
H O
OH
OO
NH.TFA
O
N
H O
O
O
O
BocHN
O
NH
O
HN
O
O
HN
O
OO
175
+
173
OO
N3
O
N
H O
O OO
N3
O
OH
174
177
121
OO
NHBoc
O
N
H O
O
176
 
Scheme 37 : Retrosynthetic strategy of tetrapeptide 173 
4.1 Synthesis of dipeptide 177 
Due to the leaving group characteristic of the azide group at  position in 
butyrolactone acid 121, treating with a strong base would easily remove the azide 
group. Our initial attempt was aimed to synthesize the dipeptide 177 from azido 
carboxylic acid 121 (Scheme 38). Coupling the azido carboxylic acid 121 with amine 178 
in the presence of coupling reagent HOBt/EDC in CH2Cl2 and DIPEA did not give the  
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dipeptide product. In that case, the conversion could not be observed. However, we 
managed to produce dipeptide 177  in  60% yield by dissolving  butyrolactone acid 121    
Reagent and conditions : a) amine 178, HOBt, HBTU, 0 
o
C- rt, THF, 24 h, 60%. 
Scheme 38: Synthesis of dipeptide 177 from butyrolactone acid 121 
and coupling reagents (HOBt and HBTU) in dry THF prior to treating them gradually 
with amine 178 without presence any base. 
 
4.2   Reductive amination and N-Boc protection 
The tert-butoxycarbonyl group is one of the protecting groups used frequently in organic 
synthesis. Being stable towards catalytic hydrogenation, basic reagents and nucleophilic 
reagents, this protecting group is considered as an ideal partner to benzyl ester and 
carbamates used in peptide synthesis.
14
  
 
O
O
H2N
O
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When dipeptide 177 in methanol was treated with Pd(OH)2/C in the presence of Boc2O, 
followed by sequentially addition of triethylsilane, the N- (tert- butoxycarbonyl) 
dipeptide 176 was yielded (Scheme 39). 
OO
N3 O
N
H O
O
177
O
O
NHBoc
O
N
H O
O
176  
Reagent and condition: (a) Boc2O (1.5 equiv), Pd(OH)2/C, Et3SiH (1.5 equiv.), MeOH, 
rt, 1.5 h 
Scheme 39: N-Boc protection of dipeptide 176 
4.3    Synthesis of tetrapeptide 173 
Prior to the synthesis of tetrapeptide 173, the tert-butoxycarbonyl group of N-Boc 
dipeptide 176, has to be initially removed using 30% of TFA in CH2Cl2  to give its 
corresponding ammonium salt 175. On the other hand, catalytic hydrogenation of benzyl 
group using Pd/C in EtOH afforded the free carboxylic acid 174 (Scheme 40). 
Subsequently, the ammonium salt 175 was coupled with preactivated dipeptide acid 174, 
using HOBt/EDC in CH2Cl2 in the presence of DIPEA, however there was no conversion 
observed, even after two days reaction. Then we carried out the coupling reaction using a 
different coupling reagent ie. HOBt/HBTU in CH2Cl2, in the presence of DIPEA, but in 
this case, after two days no conversion was observed.  
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OO
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Reagent and condition: (a) Pd/C in EtOH, quant. (b) 30% of TFA in CH2Cl2   
Scheme 40: Deprotection of tert-butoxycarbonyl and benzyl ester in 176  
In 2009, Kuwahara et al. reported the N-alkylation of butyrolactone 179 with 3-
hydroxy-2-butanone in acetonitrile
15
. They used one equivalent of NaHCO3 and five 
equivalent of MgSO4 to give the N-alkylated product 180 as depicted in Scheme 41. 
OH
O
O
N
H
O
OH
O
O
NH.TFA
a
OH
O
O
N
H
O
OH
O
O
HN
O
OH
O
179 180  
Reagent and condition :  a) MgSO4 (5 equiv.), NaHCO3 (1 equiv.), CH3CN, 75 
o
C, 72% 
Scheme 41: N-alkylation of lactone 179 with 3-hydroxy-2-butanone developed by 
Kuwahara et al. 
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By applying the above procedure, in which dipeptide acid 174 was pre-activated with 
coupling reagent, HOBt/HBTU in dry THF, followed by treatment with solution of 
dipeptide amine salt 175, NaHCO3 and MgSO4  in CH3CN at 0 
o
C to room temperature. 
The tetrapeptide 173 was obtained in 95 % yield after four days reaction time (Scheme 
42). Catalytic hydrogenation of 173 in EtOH afforded tetrapeptide acid 181. 
OO
NHBoc
O
N
H O
OH
OO
NH.TFA
O
N
H O
O
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O
BocHN
O
NH
O
HN
O
O
HN
O
ORO
175
+
173
174
181
R= CH2Ph
R= H
a
b
 
Reagent and condition:  a) HOBt/HBTU, MgSO4 (5 equiv.), NaHCO3 (1 equiv.), 
THF:CH3CN (1:1)  (b) Pd/C, H2,  EtOH, 6 h  
Scheme 42: Synthesis of - tetrapeptide 173 and - tetrapeptide acid 181 
4.4 Structural investigations of - tetrapeptide acid 181 
Circular dichorism (CD) is based on the differential in absorption of let-handed and right 
handed circularly polarized light. Therefore, the spectra of chromophores can be positive 
and negative bands in the observed wavelength range (far UV). The spectra is displayed 
using mean residue weight ellipticity [Θ]. 
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The amide chromophore (restricted rotation) in peptides or proteins are due to the low 
energy n        transition and higher energy       transition. Therefore bonds such as 
RC-bond and CO- C are responsible for the CD spectra. 
The observed bands in the CD spectra can be used as a primary indicator to predict the 
secondary structure in peptides or proteins. Each secondary structures will gives specific 
CD spectrum such as -turn, sheet, -helix and random coil as depicted in Figure 12. 
 
Figure 12 : CD spectra of the common secondary structures
16
 
In -turns (Figure 13), peptides with four amino acid residues connected by the amide 
bond. Secondary structure of peptide with -turns occurs when hydrogen bonds are 
forming between the C=O backbone and NH (i + 3). 
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-helix
-turn
-turn
 
Figure 13 : Schematic representation of the intramolecular hydrogen bond 
Secondary structure with -turn occurs when hydrogen bonding is forming between the 
C=O group of one residue and the NH of the (i + 2). Whereas -helix is defined by the 
formation of hydrogen bonding between the C=O group of one residue and the NH of the 
(i + 4). 
The - tetrapeptide acid 181 was characterized by CD spectroscopy in methanol. The 
CD spectrum was positive between 198 nm and 260 nm, with crossover at 218 nm. Two 
negative bands were observed in 181, centered at 203 nm and 213 nm with crossover at 
198 nm as depicted in Figure 14. This was the result of exiton splitting which lead to 
splitting of the           transition. The CD spectrum results, allow us to suggest that 
- tetrapeptide acid 181 was able to induce a stable helical conformation with a well-
defined arrangement of the side chains. 
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Figure 14: CD spectra - tetrapeptide acid 181 in methanol 
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Figure 15:  CD spectra of monomer 175 in methanol and - tetrapeptide acid 181 in 
methanol, TFE and methanol/water. All compounds were measured at the concentration 
of 0.3 mM. 
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In order to see if the conformational properties of - tetrapeptide acid 181 is dependent 
on the solvent, the CD spectra of the - tetramer acid dissolved in TFE and 
methanol/water were recorded. In TFE, a well-known secondary structure stabilizer, two 
negative bands were observed, centered at 210 nm and 197 nm, with crossover at 192 nm. 
The band shape remained the same in methanol. Changing TFE with methanol/water, 
increased the intensity of the negative band centered at 204 nm with a crossover at 190 
nm. The exciton splitting was observed for the - tetrapeptide acid 181 dissolved in 
methanol or TFE, but disappeared in methanol/water, suggesting that a more open 
conformation was observed (Figure 15). The CD intensity was reduced especially in 
methanol/water rather than TFE. This might due to their ability to form more favourable 
hydrogen bonding. 
 
5. The synthesis of NFmoc-Arginine--butyrolactone dipeptide as a useful 
scaffold for NPY analogs 
NFmoc-Arginine--butyrolactone 182 was envisioned to be synthesized from 139a in 
solution phase strategy (Scheme 43). 
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Scheme 43: Retrosynthetic strategy of dipeptide 182. 
The ammonium salt 139a was coupled with Fmoc-L-Arg(Pmc)-OH 183 in the presence 
of DIPEA using HOBt/HBTU in THF to yield the dipeptide 182 as depicted in Figure 17. 
Hydrogenation of the benzyl protected dipeptide 182 in EtOH  in the presence of Pd/C 
(10  mol%) furnished N-Fmoc-Arginine--butyrolactone acid 184 (Scheme 44). 
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Reagent and condition :  a) HOBt/HBTU, DIPEA, THF, 68 % (b) Pd/C, H2,  EtOH, 6 h, 
95 %. 
Scheme 44: Synthesis of N-Fmoc-Arginine--butyrolactone 182 and 183 
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6. Conclusion 
Azido acid bearing  -butyrolactone scaffold 121, could serve as useful building block for 
peptide synthesis either in solution phase nor solid phase protocols. We have synthesized 
for the first time, tetrapeptide 173 and dipeptide NFmocArg--butyrolactone 182 in the 
solution phase protocol. With these results, a wide range of unnatural peptides can be 
synthesized which lead to the exploration of conformational study of foldamers which 
may demonstrate high stability, affinity and selectivity towards natural occurring peptides 
. 
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D. SUMMARY 
5.1 Synthesis of (-) GWL 
In this work, new methodology towards the synthesis of (-) GWL 36b was synthesized in 
enantiomerically pure from benzene 69 in seven steps through lactonization of 65 as the 
key steps.  
OO
O
OTMS
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H
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Boc
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63a
656667
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O
OO
Boc
N
O
O
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N
75 36b
 
The key intermediate azido trimethylsiloxy cyclohexene 66, was synthesized from 
benzene 69. By birch reduction protocol, benzene 66 was transformed to 1,4-
cyclohexadiene 68, followed by m-CPBA epoxidation of 68 to afford epoxide 67. 
Subsequently enantioselective asymmetric ring opening of the epoxide 67 catalyzed by 
salen Cr (III) complex 70 to give the azido trimethylsiloxy cyclohexene 66 (in 68%, 86% 
ee). Reduction amination of compound 66 furnished N-Boc protected amine 65, which 
undergoes lactonization by ruthenium catalyzed oxidative cleavage of double bond to 
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give lactone lactam 63a. Finally in two steps, (-)-GWL was obtained via chemoselective 
reduction of lactone lactam carbonyl group in 63 and deprotection of Boc group 75.  
5.2        Synthesis of cis -butyrolactone ester analogs 
We have also developed a series of novel cis -butyrolactone ester analogs derived from 
azido carboxylic acid 121. 
 
O
O
N3
OH
O
O
O
N3
OR
O
O
O OR
O
+
OTMS
N3
66 121 120, 127-139
 
 
The key step was lactonisation of azido trimethylsiloxy cyclohexene 66 by ruthenium 
catalyzed  oxidative cleavage of double bond to give azido carboxylic acid 121. 
Treatment of compound 121 with several functionalized aromatic bromide under base 
condition or diazomethane or esterification with alkyl alcohol afforded cis -
butyrolactone ester analogs 
120,127-139. Most of the synthesized compounds (129, 130, 131, 132, 133, 134, 135 and 
136) showed moderate MIC activities and compounds 130, 139 showed a very modest 
MIC value. The most active one among the synthesized analogs is compound 127. 
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5.3 Synthesis of dipeptide and tetrapeptides 
We have also successfully achieved the synthesis of novel dipeptide 176, 177, 182,184 
and tetrapeptide 173, 181. Coupling of azido acid 121 and amine 178 using standard 
coupling procedure without base afforded dipeptide 177. Subsequent reduction amination 
and protection in one step gave N-Boc protected dipeptide 176. Coupling of free 
carboxylic acid 174 and amine salt 175 using standard coupling method furnished 
tetramer 173, which could be transformed into their corresponding acid 181 by catalytic 
hydrogenation of 173. In the forward sense, N-Fmoc-Arginine--butyrolactone 182 also 
could be envisioned from 139a using the same protocols. 
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Experimental Part 
 
 
1. Instruments and general techniques 
 
1
H NMR-Spectra were recorded on Bruker Avance 300 (300 MHz), Bruker Avance 400 
(400 MHz) and Bruker Avance 600 (600 MHz). The chemical shifts are reported in  (ppm) 
relative to (CDCl3, 7.26 ppm), dimethlsulfoxide (DMSO-d6, 2.49 ppm), methanol-d4 
(CD3OD, 3.34 ppm) and tetramethylsilane (TMS, 0.00 ppm) as an internal standard. The 
spectra were analyzed by first order, the coupling constant (J) are reported in Hertz (Hz). 
Characterisation of signals: s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet, bm= broad multiplate, dd = double doublet, dt = double triplet, ddd = doublet 
double doublet. Integration is determined as the relative number of atoms. Diastereomeric 
ratios were determined by comparing the integrals of the corresponding protons in the 
1
H 
NMR spectra.  
 
13
C NMR-Spectra were on Bruker Avance 300 (300 MHz), Bruker Avance 400 (400 MHz) 
and Bruker Avance 600 (600 MHz). The chemical shifts are reported in  (ppm) relative to 
(CDCl3, 77.0 ppm), dimethlsulfoxide (DMSO-d6, 39.52 ppm), methanol-d4 (CD3OD, 49.0 
ppm) and tetramethylsilane (TMS, 0.00 ppm) as an internal standard. 
 
2D- NMR-Spectra (COSY, NOESY, HMBC, HSQC) were recorded on Bruker Avance 600 
(600 MHz). 
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Melting point (m.p) were determined with a Buchi SMP 20 and are uncorrected. 
 
IR-Spectra were recorded on a Bio-Rad Excalibur FTS 3000 spectrometer, equipped with a 
Specac Golden Gate Diamond Single Reflection ATR-System. 
 
Mass spectrometry was performed on Varian MAT 311A, Finnigan MAT 95, Thermoquest 
Finnigan TSQ 7000, Nermag quadrupoles, VG ZAB high-resolution double-focusing and 
VG Autospec-Q tandem hybrid with EBEqQ configuration. High resolution mass 
spectroscopy (HRMS): The molecular formula was proven by the calculated mass. 
 
Optical rotation was measured at rt on a 241 MC Perkin-Elmer polarimeter at a wavelength 
of 589 nm (Na-D) in a 1 dm or 0.1 dm cell. 
 
CD-Spectra were measured on a JASCO model J-710/720 at the institute of Bioanalytic and 
Sensoric, University of Regensburg at 21 
o
C between 300 and 180 nm in the specific solvent, 
the number of scans ranging from 5 to 10. The length of the cylindrical cuvettes was 1.0 mm, 
the resolution was 0.2 nm, the band width 1.0 nm, the sensitivity 10-20 mdeg, the response 
2.0 s, the speed 10 nm/min. The background was subtracted to each spectrum. The 
absorption value is measured as Molar Ellipticity per residue (degcm
2
 dmol
-1
). The spectra 
were smoothed by the adjacent averaging algorithm with the Origin 6.0 program. 
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X-ray analysis was performed by the crystallography laboratory of the University of 
Regensburg (STOE-IPDS, Stoe & Cie GmbH). 
 
Antituberculosis assay was performed in the Institute for Tuberculosis Research, College of 
Pharmacy, University of Illinois, Chicago, USA.  
 
Mycobacterium tuberculosis. The inhibitory activity of fractions and compounds against M. 
tuberculosis was determined using the microplate Alamar Blue assay and the low oxygen-
recovery assay. Virulent H37Rv strain was used in both assays.  
 
Cytotoxicity was evaluated using green monkey kidney cells (Vero). Cell viability was 
measured using the CellTiter 96 aqueous nonradioactive cell proliferation assay. 
 
Chiral HPLC was performed in the Institute of Organic Chemistry, University of 
Regensburg on a Kontron Instruments 325 System (HPLC 335 UV detector,  = 254 nm, 
Chiracel OD/OD-H, OJ as chiral stationary phase. 
 
Thin layer chromatography (TLC) was performed on alumina plates coated with silica gel 
(Merck silica gel 60 F 254, layer thickness 0.2 mm). Visualization was accomplished by UV-
light (wavelength  = 254 nm), vanillin/sulphuric acid and ninhydrin stain. 
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Column chromatography was performed on silica gel (Merck Geduran 60, 0.063-0.0200 
mm mesh) and lash-silica gel 60 (0.040-0.063 mm mesh). 
 
Solvents were performed according to standard laboratory methods. THF, diethyl ether, 
ethanol and DMF were distilled before used. Dichloromethane was distilled over calcium 
hydride. Methanol or ethanol was refluxed with Mg/I2 for 3 h, distilled and stored under 
nitrogen over 4 
o
A molecular sieves. Acetic anhydride was refluxed with P2O5 for 2 h, 
distilled and stored under nitrogen. All reactions with oxygen or moisture sensitive reactant 
were performed under nitrogen atmosphere. 
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1. Synthesis of compounds 
 
2.1 (-)-Geissmann Weiss Lactone (GWL) 
 
 
 
Cyclohexa-1,4-diene (68)  
To a two liter three neck round bottom flask equipped with mechanical stirrer and under N2 
atmosphere was flowed in 750 mL ammonia at -78 
o
C. With vigorously stirred, dry benzene 
100 mL (88.2 g, 1.13 mol) was added slowly using dropping funnel into the liquid ammonia 
until white precipitate formed. 
Sodium metal (40 g) was then added in small quantities within 1 h and the reaction mixture 
became deep blue during this periods. The mixture was allowed to stir for another 2 h. 
Ethanol (150 mL) was then added into the reaction mixture and the mixture was keep stirring 
for overnight. 
500 mL cooled H2O was added into white precipitate solution, slowly by dropping funnel. 
The organic layer was collected and washed with 500 mL H2O, the aqueous layer was 
extracted back with 50 mL of n-pentane and the combined organic layer was dried with 
MgSO4, filtered to give 70.1 g (40.1%) of 1,4–cyclohexadiene  (68). 
 
1
H-NMR (300 MHz, CDCl3):  = 5.70 (s, 4H), 2.60 (s, 4H). 
13
C-NMR (75.5 MHz, CDCl3 ): 
 = 128.3 (C=C), 124.4 (C=C), 25.8 (CH2). 
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7-Oxabicyclo [4.1.0]hept-3-ene (67) 
 To a 1 liter round- bottom flask with a magnetic bar was charge with 1,4–cyclohexadiene 68 
(3.38 g, 42.1 mmol, 1.1 equiv.), 300 mL of DCM and K2HPO4  (3.61 g, 20.7 mmol, 1equiv.) 
in 2 mL of H2O. The flask was placed in ais bath (0 
o
C) and m-CPBA (70%, 10.2 g, 41.3 
mmol, 1 equiv.) was added portion wise in small quantities. The white solution was stirred 
for several hours and the reaction mixture was allowed to warm up to room temperature. The 
reaction mixture was stirred for another 18 h at room temperature. The white solid was 
filtered by vacum filtration and the filtrate was washed with 50 mL of saturated NaHCO3, 50 
mL of 5% Na2SO3, 50 mL of saturated NaHCO3, water (50 mL), brine (50 mL), dried over 
MgSO4 and concentrated under vacuo to afford 3.58 g, (88.9%) of desired product as 
colourless oil . The product could be purified by distillation (23 mmHg, 60 
o
C).  
 
1
H-NMR (300 MHz, CDCl3):  = 5.48 (s, 2H), 3.73 (s, 2H), 2.56 (d, J= 17.6, 2H), 2.45 (d, 
2H, J = 17.6, 2H). 
13
C-NMR (75.5 MHz, CDCl3):  = 121.6 (C=C), 51.3 (CH), 24.9 (CH2). 
IR (Film):  ~  = 2993, 2891, 2824, 1429, 1349, 1214, 1183, 864, 737, 650 cm
-1
. 
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OTMS
N3
66  
 
(1R,6R)-6- Azidocyclohex-3-enyloxy trimethylsilane (66) 
To a mixture of epoxide 67 (0.61 g, 6.32 mmol, 1 equiv.) in 2.1 mL of Et2O was added 
catalyst complex 70 (0.088 mg, 0.126 mmol, 2 mol%). The mixture was stirred for 15 
minutes and subsequently trimethylsilylazide (0.88 mL, 6.63 mmol, 1.05 equiv.) was added 
slowly. After the mixture was  stirred for 46 h at room temperature then the solvent was 
evaporated under reduced pressure to give yellowish crude product, which was purified by 
column chromatography on silica gel (petroleum ether: ethyl acetate, 9:1) to yield  0.84 g  
(68 %) of 66 as yellowish oil. 
 
Rf = 0.83 (SiO2, hexanes/ethyl acetate 9:1);  20D = -14.8 (c = 0.4, CH2Cl2), 86 % ee; (Lit
13a
: 
72%, 81% ee) 
1
H-NMR (300 MHz, CDCl3):  = 5.48-5.61 (m, 2H, CH Olefin), 3.73-3.84 (m, 1H, 
(CH3)SiOCH), 3.49-3.59 (m, 1H, N3CH), 2.32-2.48 (m, 2H, N3CHCH2), 2.08-2.20 (m, 1H, 
(CH3)SiOCHCH2), 1.90-2.03 (m, 1H, (CH3)SiOCHCH2), 1.98  (s, 9H, TMSO); 
13
C-NMR 
(75.5 MHz, CDCl3 ):  = 124.6 (C=C), 123.9 (C=C), 71.9 (Cquart), 62.9 (Cquart), 34.7 (CH2), 
30.9 (CH2), 0.0 (TMSO-C); IR (Film): 
~  = 2957, 2905, 2107, 1438, 1250, 1140, 881, 840, 
748, 667 cm
-1
.  MS [CI, NH3]: m/z (%) = 212.1 (11) [M + H
+
], 184.1 (29.9) [(M + H
+
) – N2]. 
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OTMS
N
H
O
O
65  
tert-Butyl (1S,6S)-6-(trimethylsilyloxy) cyclohex-3-enylcarbamate (65) 
To a stirred mixture of azido trimethylsiloxy cyclohexene 66 (0.2 g, 1.02 mmol, 1 equiv.) in 
3.4 mL ethanol, was added tert-butoxycarbonyl (Boc2O) (0.45 g, 2.04 mmol, 2 equiv.) and 
20% Pd(OH)2/C (10.2 mg) at room temperature. Then to this mixture, triethylsilane (0.33 
mL, 2.04 mmol, 2 equiv.) was added sequentially and the mixture was stirred for 20 h under 
N2 atmosphere. The mixture was filtered  through Celite and the filtrate was concentrated 
under reduce pressure to remove the solvent to give yellowish solid which was purified by 
column chromatography on silica gel (petroleum ether: ethyl acetate, 15:0.5) to yield  0.26 g 
(88%) of 65 as yellowish solid and  0.017 mg (8%) of  16 as white solid. 
 
Rf = 0.75 (SiO2, hexanes/ethyl acetate 21:7) m.p. 79-81 °C  20D = +35.5 (c = 0.4, CH2Cl2) 
1
H-NMR (300 MHz, CDCl3):  = 5.46-5.57 (m, 2H, CH olefin), 4.45 (bs, IH, NH), 3.67-3.76 
(m, 1H, CHOSi(CH3)3), 3.53-3.65 (m, 1H, CHNBoc), 2.55 (m, 1H, CH2CHNBoc), 2.26 (m, 
1H, CH2CHNBoc), 2.05 (m, 1H, CH2CHOSi(CH3)3), 1.88 (m, 1H, (CH2CHOSi(CH3)3), 1.48 
(s, 9H, Boc), 0.90 (s, 9H, TMSO); 
13
C-NMR (75.5 MHz, CDCl3 ):  = 155.5 (CO, Boc), 
124.2 (C=C), 78.9 (Cquart, CHOTMS) ,68.9 (Cquart, Boc-C), 50.8 (Cquart, CHNBoc), 32.9 
(CH2CHOTMS), 29.9 (CH2CHNBoc), 28.2 (Boc-C), 0.0 (TMSO-C); IR (Film):                    
~  = 3340, 2976, 1689, 1531, 1366, 1309, 1249, 1170, 1102, 1067, 887, 840, 749, 661 cm
-1
.  
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MS [CI, NH3] m/z (%) = 285.1 (100); HRMS (Cl, NH3); Calculated for [C14H27NO3Si: 
285.1760, found 285.1758. 
 
 
tert-Butyl(3R,4R)-1,6-dioxo-4-(trimethylsiloxy)hexan-3-ylcarbamate(64)  
To a stirred solution of N-Boc-trimethylsiloxy cyclohexene amine (1.016 g, 3.56 mmol, 1 
equiv.), NaHCO3 (0.03 g, 0.36 mmol, 0.1 equiv.) and methanol (0.36 ml, 8.9 mmol) in DCM 
(4.5 mL) was treated with ozone at -78 
o
C. Subsequently, dimethyl sulfide (0.54 mL, 7.33 
mmol) was added and the reaction mixture was allowed to warm up to room temperature and 
stirred for 12 h at room temperature. Then, the mixture was extracted with water for three 
times  (6 mL of water each), dried over MgSO4, filtered and concentrated under reduce 
pressure to give the crude dialdehyde, which was purified by column chromatography on 
silica gel (petroleum ether : ethyl acetate, 15 : 3) to afford 0.70 g (62.0%) of 64 as colorless 
oil. 
 
Rf = 0.24 (SiO2, hexanes/ethylacetate 15:3);  
20
D = +20.5 (c = 0.4, CH2Cl2) 
 
1
H-NMR (300 MHz, CDCl3):  = 9.78 (t, 1H, CHO), 9.72 (t, 1H , CHO), 5.41 (d, 1H, J = 
4.1, NH), 4.63-4.74 (m, 1-H, (CH3)SiOCH), 4.38-4.51 (m, 1-H, BoCNHCH), 2.60-2.78 (m,  
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1H, (CH3)SiOCHCH2), 2.35-2.45 (m, 1H, (CH3)SiOCHCH2), 2.02-2.42 (m, 1H, 
BoCNHCHCH2), 1.81-1.98 (m, 1H, BoCNHCHCH2), 1.49 (s, 9-H, BoC), 0.11 (s, 9-H, 
TMSO); 
13
C-NMR (75.5 MHz, CDCl3 ):  = 221.7 (2CHO), 154.1 (CO, BoC), 73.3 (Cquart, 
Boc-C), 70.2 (Cquart, TMSOC), 56.9 (Cquart, Boc-NHC), 42.3 (Boc-NHCHCH2), 41.3 
(TMSOCHCH2), 28.6 (Boc-C), 0.0 (TMSO-C); MS [CI, NH3] : m/z (%) = 259.1 (45), 159.1 
(100) [M – C4H8 + CO2]. 
 
 
 
(3aS, 6aS)-tert-Butoxycarbonyl-cis-dihydrofuro(3,2-b) pyrrole-2,5-dione (63a) 
To a stirred solution of 65 (0.530 g, 1.8 mmol) in 55 mL of biphasic solution of 
CCl4:MeCN:H2O (1:1:2) was added RuCl3.3H2O (0.032 g, 8.3 mol%) at  0 
o
C, followed by 
NaIO4 (1.588 g,  4.1 equiv.) portion wise. The reaction mixture was stirred for 8 h at 0 
o
C. 
Then the mixture was diluted with 30mL of water and extracted with DCM (15 mL x 3), 
followed by 1-butanol (15 mL x 3). The combined organic layer was dried over by MgSO4 
and the solvent was evaporated under reduced pressure to give brownish crude product, 
which was purified by column chromatography on silica gel (ethyl acetate:methanol, 9:1) to 
yield 0.268 g (62 %) of 63a as a white solid.  
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Rf = 0.71 (SiO2, ethylacetate/methanol 9:1); m.p. 162-164 °C (lit
10
, m.p 163-164 °C),  20D = 
+53.8 (c = 0.4, DMF) (lit
10
,  20D = +61.7 (c = 1, DMF)
 
1
H-NMR (300 MHz, CDCl3):  = 5.01-5.09 (ddd, J = 5.1, 5.5, 2.7, 1H, CHOCO), 4.74-4.81 
(ddd, J = 4.8, 6.0, 2.2,  1H , CHNBoc), 2.89-2.98 (m, 4H,CH2CONBoc, CH2CHNBoc), 1.51 
(s, 9H, BoC); 
13
C-NMR (75.5 MHz, CDCl3 ):  = 173.7 (Cquart, CO), 169.8 (Cquart, 
CONBoc), 149.8 (Cquart, CO-Boc), 84.7 (CHOCO), 73.5 (Cquart, Boc-C), 57.9 (CHNBoc), 
38.6 (CH2CONBoc), 35.6 (CH2NBoc), 28.0 (Boc-C); IR (Film): 
~  = 1781, 1768, 1721, 
1356, 1324, 1251, 1225, 1186, 1149, 1047, 1022, 933, 907, 836 cm
-1
.MS [CI, NH3] : m/z 
(%) = 259.1 (44)  [M  + NH4
+
]; Elemental analysis calcd (%) for C11H15NO5 (241.1): C 54.9, 
H 6.3, N 5.9 ; found C 54.99, H 6.36,  N 5.44. 
 
  
O
N
O
O
O
75  
 
(3aS,6aS)-tert-Butyl 2- oxotetrahydro-2H-furo(3,2-b) pyrrole-4(5H) carboxylate (75) 
To a stirred solution of 63 (0.10 g, 0.41 mmol) in 10 ml dry THF was added borane DMS 
(0.12 mL, 1.24 mmol, 3 equiv.) dropwise at 0 
o
C to room temperature, then the  mixture was 
leaved stirred for 17 h under N2 atmosphere. MeOH (2 mL) was added until no evolution of 
gas, then the solvent was removed by rotary evaporator (repeated 3 times).  Organic layer  
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was dried over by MgSO4 and the solvent was evaporated under reduced pressure to give 
white solid product, which was purified by column chromatography on silica gel (ethyl 
acetate:methanol, 4:6) to yield g 0.056 g (53%) of 75 as white solid and side product 79 (10 
mg) 11% also as white solid. 
 
Rf = 0.57 (SiO2, hexane/ethyl acetate 4:6); m.p. 105-107
o
C, lit
23
: 106-107
o
C;  20D = +95.0 (c 
= 0.4, MeOH), lit
23
:  20D = +96.0 (c = 0.4, MeOH) 
1
H-NMR (300 MHz, CDCl3):  = 5.01-5.10 (m, 1H, CHOCO), 4.38-4.50 (m, 1H, CHNBoc), 
3.61-3.86 (m, 1H, CH2NBoc), 3.29-3.42 (m, 1H, CH2NBoc), 2.72-2.88 (m, 2H, 
CH2CHNBoc), 2.28-2.40 (dd, J =  14, 6.2 Hz, 1H, CH2CHO), 1.96-2.12 (m,1H, CH2CHO), 
1.45 (s, 9H, Boc); 
13
C-NMR (75.5 MHz, CDCl3 ):  = 176.45 ((Cquart, CO), 154.52 (Cquart, 
CO-Boc), 83.12 (CHOCO), 80.52 ((Cquart, Boc-C), 57.87 (CHNBoc), 44.26 (CH2NBoc), 
36.64 (CH2COO), 30.70 (CH2CHO), 28.42 (Boc-C); ); IR (Film): 
~  = 2978, 2933, 2872, 
1766, 1698, 1394, 1366, 1230, 1160, 1116, 1092, 1036, 982, 904, 843, 774 cm
-1
.  MS [CI, 
NH3] : m/z (%) = 227.1 [M
+
]. 
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O
N
O
O
79  
(3aS,6aS)-tert-Butyl tetrahydro-2H-furo(3,2-b) pyrrole-4(5H)  carboxylate (79) 
Rf = 0.42 (SiO2, hexane/ethylacetate 4:6); m.p. 83-85 
o
C  20D = +10.8 (c = 0.4, CH2Cl2) 
1
H-NMR (300 MHz, CDCl3):  = 4.28-4.36 (m, 1H, CHOCH2), 3.85-3.92 (bs, 1H, 
CHNBoc), 3.55- 3.72 (m, 2H, CH2O), 3.20-3.35 (m, 2H, CH2NBoc), 3.55-2.02 (m, 4H, 
CH2CHO, CH2CH2O), 1.38 (s, 9H, Boc); 
13
C-NMR (75.5 MHz, CDCl3 ):  = 155.88 (Cquart, 
CO-Boc), 79.97 (CHO), 70.66 (Cquart, Boc-C), 59.00 (CHNBoc), 57.84 (CH2O),  43.49 
(CH2NBoc), 31.06 (CH2CHNBoc), 30.75 (CH2CHO), 28.43 (Boc). IR (Film): 
~  = 2976, 
2938, 2888, 1650, 1410, 1366, 1251, 1162, 1128, 1068, 1013, 980, 866, 770 cm
-1
. MS [CI, 
NH3] : m/z (%) =  213.1 [M
+
]. 
 
 
OO
H.HCl
N
36b  
 
(3aS,6aS)-Hexahydro-2H-furo[3,2-b]pyrrol-2-one hydrochloride (36b) 
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To a compound 75 (31 mg, 0.14 mmol) was treated with saturated HCl in dry ethylacetate (8 
mL) at 0 
o
C for 3 h. Then the solvent was removed in vacuo, dried on oil pump overnight to 
afford 36b (68%) as a white solid.  
 
Rf = (SiO2, hexane/ethyl acetate 4:6); m.p. 181-183 °C, lit
23
: 182-184 
o
C;  20D = -40.0 (c = 
0.4, MeOH), lit
23
:  20D = -42.0 (c = 0.4, MeOH) 
1
H-NMR (300 MHz, DMSO):  = 9.65 (bs, 2H, NH2Cl), 5.15 (m, 1H, CHO), 4.34 (ddd, J = 
1.6, 2.4, 1.9 Hz, 1H, CHN), 3.24-3.44 (m, 2H, CH2N), 3.05-3.16 (m, 2H, CH2COO), 2.02-
2.20 (m, 2H, CH2CH2N); 
13
C-NMR (75.5 MHz, CDCl3 ):  = 174.30 (Cquart, CO), 82.12 
(CHO), 57.57 (CHN), 43.01 (NCH2), 31.77 (CH2COO), 30.57 (NCH2CH2). IR (Film): 
~   =  
3300, 2923, 1771, 1723, 1389, 1201, 1165, 1108, 1039, 1023, 991, 906, 801, 670, 615, 
582,543 cm
-1
. MS [CI, NH3] : m/z (%) =  113.1 [M
+
]. 
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2.2        cis (-)--butyrolactone derivatives 
 
OO
N3 O
OH
121  
 
 2-(2S,3S)- 3-Azido-5-oxotetrahydrofuran-2-yl) acetic acid (121) 
To a stirred solution of 66 (2.73 g, 13.9 mmol) in 400 mL of biphasic solution of CCl4: 
MeCN: H2O (1:1:2) was added RuCl3.3H2O (0.241 g, 8.3 mol%) at 0 
o
C, followed by NaIO4 
(12.256 g, 4.1 equiv.) portion wise. The reaction mixture was stirred for 19 h at 0 
o
C. Then 
the mixture was diluted with 30 mL of water and extracted with DCM (15 mL x 3), followed 
by 1-butanol (15 mL x 3). The combined organic layer was dried over by MgSO4 and the 
solvent was evaporated under reduced pressure to give brownish crude product, which was 
purified by column chromatography on silica gel (ethyl acetate:methanol, 9:1) to yield 1.593 
g (61 %) of 121 as yellowish  solid. The product could be recrystallized by dissolving in 
(DCM:EtOAc, 1:1) to give pure azido carboxylic acid. 
Rf = 0.33 (SiO2, ethyl acetate/methanol 9:1); m.p. 126-128 °C  
20
D = +15.6 (c = 0.4, 
CH2Cl2);  
 
1
H-NMR (300 MHz, DMSO):  = 12.66 (s, 1H, OH), 4.88-4.95 (m, 1H, CH2CHO), 4.65-
4.72 (m, 1H, N3CH), 3.15 (dd, J = 17.6, 6.4 Hz, 1H, N3CHCH2), 2.65-2.88 (dddd, J = 16.9, 
6.2, 7.7, 7.7 Hz, 2H, CH2COOH), 2.59 (dd, J = 17.7, 1.2 Hz, 1H, N3CHCH2); 
13
C-NMR  
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(75.5 MHz, DMSO):  = 174.03 (Cquart, CO), 170.88 (Cquart, COOH), 78.29 (CH2CHO), 
60.12 (N3CH), 35.56 (N3CHCH2), 34.28 (CH2COOH); IR (Film): 
~  = 2920, 2098, 1776, 
1717, 1409, 1356, 1283, 1215, 1187, 1158, 1064, 1020, 996, 919, 878, 785, 654 cm
-1
. MS 
[Cl, NH3]: m/z (%) 185.0; HRMS (Cl, NH3); Calculated for [C6H7N3O4]: 185.0437, found 
185.0440. 
 
OO
N3 O
N
H
CH3
123  
 
2-((2S,3S)-3- Azido-5-oxotetrahydrofuran-2-yl)-N-(1-phenylethyl)acetamide (123)  
To a stirred  solution of  azido carboxylic acid 121 (30.0 mg, 0.16 mmol)  in dry THF (2 mL) 
was added HOBt (24.1 mg, 1.1 equiv.), DCC (43.5 mg, 1.3 equiv.) and (R)- 
phenylethylamine (22.7 μL, 1.1 equiv.) at 0 oC. Then the ice bath was removed and the 
reaction mixture was stirred for 24 h at room temperature. The solvent was removed by 
rotary evaporator. Then the white solid was dissolved in 5 mL EtOAc and filtered. The 
filtrate was washed with 1 M HCl (2 mL), saturated NaHCO3 (5 mL) and brine (5 mL). The 
organic layer was dried over by MgSO4 and the solvent was evaporated under reduced 
pressure to give white solid crude product, which was purified by column chromatography 
on silica gel (petroleum ether: ethyl acetate, 4:6) to yield  24.6 mg  (55 %) of 123 as white 
solid. 
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Rf = 0.48 (SiO2, petroleum ether: ethyl acetate, 4:6);  20D = +59.1   (c = 0.4, CH2Cl2) 
1
H-NMR (300 MHz, CDCl3):  = 7.28-7.40 (m, 5H, Ph), 5.94 (bs, NH), 5.08-5.18 (m, 1H, 
CH2CHO), 4.88-4.97 (m,1H, N3CH), 4.59 (t, 1H, CH3CHPh), 2.63-2.95 (m, 4H, CH2CHN3,  
CH2CON); 
13
C-NMR (75.5 MHz, DMSO):  = 176.36 (Cquart, CO), 175.4 (Cquart, CO), 128.3 
(Cquart,Bz-C), 126.12 (Ph-C), 77.8 (CH2CHO), 60.16 ( CH3CHPh), 49.19 (N3CHCH2), 36.05 
(N3CHCH2), 33.97 (CH2CON), 21.81 (CH3). IR (Film): 
~   = 3300, 2929, 2111, 1777, 1645, 
1541, 1260, 1196, 1152, 1018, 763, 700; MS [Cl, NH3]: m/z (%) 306.1 [M + NH4
+
], 289.1 
[M + H
+
]; HRMS (Cl, NH3); Calculated for [C14H16N4O3]: 288.1222, found 288.1222. 
 
 
OO
N3 O
O
120  
 
Benzyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl) acetate (120) 
To a stirred solution of azido carboxylic acid 121 (152 mg, 0.82 mmol) in dry DMF (6 mL) 
was added NaHCO3 (414.0 mg, 6 equiv.), followed by benzyl bromide (157.0 μL, 1.6 equiv.) 
sequentially at room temperature. The reaction mixture was stirred for 43 h at room 
temperature. Then the mixture was diluted with   4 mL of EtOAc: H2O (1:1) solution and the 
solution was separated. The aqueous layer extracted with EtOAc and the combined organic  
 
 
 
 99 
 
layer was dried over by MgSO4, concentrated under reduced pressure to give yellowish crude 
oil product, which was purified by column chromatography on silica gel (petroleum:ethyl 
acetate, 6:4) to yield 50.1 mg (69 %) of 120 as yellowish  oil and side product 127,  8.0 mg 
(12%) as white solid. 
 
Rf = 0.51 (SiO2, ethyl acetate/methanol 9:1); m.p. 76-78 °C  20D = +34.4    (c = 0.4, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 7.33-7.41 (m,5H, Ph), 5.17(s, 2H, CH2Ph), 4.85-4.93 
(m,1H, CH2CHO), 4.52-4.58 (ddd, J = 1.4, 1.6, 1.4 Hz, 1H, N3CH), 2.85-3.05 (m, 3H, 
CH2CHN3, CH2COOBz), 2.68 (dd, J = 17.8, 1.4 Hz, CH2CN3); 
13
C-NMR (75.5 MHz, 
CDCl3):  = 172.88 (Cquart, CO), 169.34 (Cquart, COOBz), 135.19 (Cquart, Bz), 128.72 (Ph-C), 
128.61 (Ph-C), 128.40 (Ph-C), 78.04 (CH2CHO), 67.08 (CH2Ph), 59.61(CHN3), 35.66 
(CH2CHN3), 34.26 (CH2COOBz); IR (Film): 
~   = 2100, 1776, 1717, 1421, 1396, 1342, 
1311, 1275, 1196, 1151, 1121, 1031, 990, 937, 899, 741, 700 cm
-1
.   MS [Cl, NH3]: m/z (%) 
293.1 [M + NH4
+
]; HRMS (Cl, NH3); Calculated for [C13H13N3O4]:  275.0906, found 
275.0901.  
 
 
 
 
 
OO
O
O
127
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(S)-Benzyl 2-(5-oxo-2,5-dihydrofuran-2-yl) acetate (127) 
Rf = 0.35 (SiO2, petroleum ether/ethyl acetate 6:4);  20D = +47.6 (c = 0.4, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 7.56 (dd, J = 5.6, 1.5 Hz, 1H, CHCHCO), 7.30-7.38 (m, 
5H, Ph-H), 6.14 (dd, J = 5.8, 1.9 Hz, 1H, CHCO), 5.39-5.44 (m, 1H, CHCH2CO), 5.16 (s, 
1H, CH2Ph), 2.88 (dd, J = 16.5, 7.3 Hz, 1H, CH2COO), 2.68 (dd, J = 16.5, 7.1 Hz, 1H, 
CH2COO); 
13
C-NMR (75.5 MHz, CDCl3):  = 172.29 (Cquart, COOBn), 168.80 (Cquart, CO), 
155.38 (C=C), 135.16 (Cquart, Bn), 128.71 (Ph-C), 128.61 (Ph-C), 128.45 (Ph-C), 122.19 
(C=C), 78.9 (CHCH2CO), 67.13 (CH2-Ph), 37.81 (CH2COO); IR (Film): 
~  = 1760, 1730, 
1498, 1456, 1389, 1335, 1268, 1155, 1108, 1080, 1041, 923, 815, 739, 697 cm
-1
. MS [Cl, 
NH3]: m/z (%) 232.1; HRMS (Cl, NH3); Calculated for [C13H12O4]:  232.0736, found 
232.0732. 
 
 
 
 
 
 
 
 
 
 
OO
N3 O
O
128  
Methyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate (128) 
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To a stirred solution of azido carboxylic acid 121 ( 100 mg, 0.54 mmol) in dry Et2O ( 5  mL) 
was added freshly prepared diazomethane (5 mL in diethyl ether) (in excess) at 0 
o
C to room 
temperature, then the  mixture was leaved stirred for overnight. The reaction mixture was 
diluted with 5 mL of diethyl ether and subsequently, 10% of aqueous acetic acid was added 
to remove an excess of diazomethane. The layer was separated and the aqueous layer was 
extracted with diethyl ether (5 mL x 3) and the combined organic layer was washed with 
saturated NaHCO3, dried over by MgSO4 and the solvent was evaporated under reduced 
pressure to give brownish crude product, which was purified by column chromatography on 
silica gel (petroleum ether:ethyl acetate, 6:4) to yield   99.1 mg (92 %) of 128 as yellowish  
oil. 
 
Rf = 0.53   (SiO2, petroleum ether/ethylacetate 6:4);  20D = +55.2    (c = 0.4, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3): ):  = 4.82-4.92 (m, 1H, CH2CHO), 4.55 (ddd, 1.6,1.6, 1.6 Hz, 
1H, CHN3), 3.66 (s,3H, OCH3),  2.94 (d, J =  6.7 Hz, 1H, CH2CHN3), 2.82-2.88 (m, 2H, 
CH2COOCH3), 2.62 (dd, J = 17.8, 1.4 Hz, 1H, CH2CHN3); 
13
C-NMR (75.5 MHz, CDCl3):  
= 172.05 (Cquart, CO), 168.96 (Cquart, COOMe), 77.11 (CH2CHO), 58.66 (OCH3), 51.22  
(CH2CHN3), 34.66 (CH2CHN3), 32.99 (CH2COOMe); IR (Film): 
~  = 2958, 2107, 1787, 
1732, 1438, 1280, 1151, 1023, 999, 667, 553cm
-1
. MS [Cl, NH3]: m/z (%) 217.0 [M + NH4
+
] 
; HRMS (Cl, NH3); Calculated for [C7H9N3O4:  199.0422 ,  found 199.0593. 
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OO
N3
O
O
O F
F
F
129
 
3-(Trifluoromethoxy)benzyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate (129, 
CDCl3) 
To a stirred solution of azido carboxylic acid 121 (60.0 mg, 0.32 mmol) in dry DMF (2 mL) 
was added NaHCO3 (163.0 mg, 6 equiv.), followed by trifluoromethoxy benzyl bromide 
(84.0 μL, 1.6 equiv.) sequentially at room temperature. The reaction mixture was stirred for  
48 h at room temperature. Then the mixture was diluted with   4 mL of DCM: H2O (1:1) 
solution and the solution was separated. The aqueous layer  extracted with DCM and the 
combined organic layer was dried over by MgSO4, concentrated under reduced pressure to 
give yellowish crude oil product, which was purified by column chromatography on silica 
gel (petroleum:ethyl acetate, 6:4) to yield  62.1 mg  (54 %) of 121 as yellowish  oil and side 
product  130  8.0 mg (3%) as yellowish oil. 
Rf = 0.45   (SiO2, petroleum:ethylacetate 6:4);  
20
D =  +19.3  (c = 0.3, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 7.37-7.45 (dd, J = 7.8, 7.7 Hz, 1H, Ar), 7.25-7.34 (dd, J = 
7.3, 3.8 Hz, Ar), 7,16-7.24 (m, 2H, Ar), 5.18 (s, 2H, CH2Ar), 4.55-4.95 (m,1H, CH2CHO), 
4.51-4.59 (m, 1H, N3CH), 2.87-3.06 (m, 3H, CH2CHN3, CH2COOBz), 2.68 (dd, J = 17.9, 1.3 
Hz, CH2CN3); 
13
C-NMR (75.5 MHz, CDCl3):  = 172.84 (Cquart, CO), 169.23 (Cquart, 
COOAr), 149.40 (Cquart, Ar), 137.49 (Cquart, Ar), 130.16 (Ar-C), 126.46 (Cquart,CF3), 122.13 
(Ar-C ), 120.91 (Ar-C ) 120.66 (Ar-C ),  77.91 (CH2CHO), 65.96 (CH2Ph), 59.54 (CHN3),  
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35.57 (CH2CHN3), 34.20 (CH2COOAr); IR (Film): 
~   = 2110, 1784, 1737, 1428, 1313, 
1144, 1022, 867, 797, 701, 633 cm
-1
.   MS [Cl, NH3]: m/z (%) 359.00 [M
+.
]; HRMS (Cl, 
NH3); Calculated for [C13H13N3O4]:  359.0729, found 359.0737.  
 
 
(S)-3-(Trifluoromethoxy)benzyl 2-(5-oxo-2,5-dihydrofuran-2-yl)acetate (130, CDCl3)  
Rf = 0.40 (SiO2, petroleum ether/ethylacetate 6:4);  20D = +75.0 (c = 0.15, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 7.57-7.68 (dd, J = 5.8, 1.6 Hz, 1H, CHCHCO), 7.30-7.38 
(m, 1H, Ar-H), 7.27-7.32 (m, 1H, Ar-H), 7.17-7.24 (m, 2H, Ar-H), 6.14-6.20 (dd, J = 5.6, 2.0 
Hz, 1H, CHCO), 5.36-5.46 (m, 1H, CHCH2CO),  2.88-3.14 (dd, J = 16.5, 7.3 Hz, 1H, 
CH2COO), 2.66-2.70 (dd, J = 16.6, 7.3 Hz, 1H, CH2COO); 
13
C-NMR (75.5 MHz, CDCl3):  
= 170.7 (Cquart, COOAr), 168.60 (Cquart, CO), 160.18 (Cquart, Ar), 155.05 (Cquart, olefin) 
(130.19 (Cquart, Ar), 126.55 (Ar-C), 122.39 (C=C), 120.98 (Ar-C), 78.9 (CHCH2CO), 66.09 
(CH2-Ar), 37.77 (CH2COO); IR (Film): 
~  = 1809, 1738, 1453, 1389, 1247, 1213, 1151, 
1110, 1081, 1042, 1002, 863, 818, 795, 703, 634 cm
-1
. MS [Cl, NH3]: m/z (%) 334.06 [M + 
NH4
+
]; Elemental analysis calcd (%) for C14H11F3O5 (316.23): C 53.17, H 3.51, F 18.02; 
found C 54.19, H 4.13, F 17.99. HRMS (Cl, NH3); Calculated for [C14H11F3O5]:  316.0559, 
found 316.0560. 
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OO
N3
O
O
CN
131  
 
4-Cyanobenzyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate (131, CDCl3)  
To a stirred solution of azido carboxylic acid 121 (60.0 mg, 0.32 mmol) in dry DMF (2 mL) 
was added NaHCO3 (181.0 mg, 4 equiv.), followed by 4-bromo methyl benzonitrile, (102.0 
mg, 1.6 equiv.) sequentially at room temperature under nitrogen atmosphere. The reaction 
mixture was stirred for 24 h. Then the mixture was diluted with   4 mL of DCM: H2O (1:1) 
solution and the solution was separated. The aqueous layer  extracted with DCM and the 
combined organic layer was dried over by MgSO4, concentrated under reduced pressure to 
give yellowish crude oil product, which was purified by column chromatography on silica 
gel (petroleum:ethyl acetate, 6:4) to yield  58.0 mg (60%) of 131 as yellowish oil and side 
product 132  3.0 mg (4%) as yellowish oil 
 
Rf = 0.20   (SiO2, petroleum: ethyl acetate 6:4);  
20
D = +20.0 (c = 0.2, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 7.62-7.69 (dd, J = 8.23, 1.7 Hz, 2H, Ar), 7.42-7.49 (dd, J = 
8.51, 1.4 Hz, 2H, Ar ),  5.21(s, 2H, CH2Ar), 4.86-4.95 (m,1H, CH2CHO), 4.54-4.59 (m, 1H, 
N3CH), 2.87-3.06 (m, 3H, CH2CHN3, CH2COOAr), 2.68 (dd, J = 18.11, 1.4 Hz, CH2CN3); 
13
C-NMR (75.5 MHz, CDCl3):  = 172.81 (Cquart, CO), 169.20 (Cquart, COOAr), 140.49  
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(Cquart, Ar), 132.50 (Ar-C), 128.82 (Ar-C), 118.49 (Cquart, Ar), 112.26 (CN), 77.80 
(CH2CHO), 65.70 (CH2Ar), 59.51 (CHN3), 35.56 (CH2CHN3), 34.24 (CH2COOAr); IR 
(Film): ~   = 2229, 2109, 1782, 1734, 1412, 1345, 1268, 1147, 1020, 928, 818, 735, 710, 547 
cm
-1
.   MS [Cl, NH3]: m/z (%) 300.0 [M
+.
]; HRMS (Cl, NH3); Calculated for [C14H12N4O4]:  
300.0859, found 300.0863.  
 
OO O
O
CN
132  
(S)-4-Cyanobenzyl 2-(5-oxo-2,5-dihydrofuran-2-yl)acetate (132, CDCl3)  
Rf = 0.16  (SiO2, petroleum: ethylacetate 6:4); m.p. 72-74 °C  20D =  +40.6 (c = 0.2, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 7.61-7.65 (dd, J = 8.00, 1.5 Hz, 2H, Ar), 7.60-7.77 (d, J = 
6.06, 1H, Olefin),  7.44-7.59 (dd, J = 8.45, 1.5 Hz, 2H, Ar ), 6.15-6.23 (d, J = 7.06, 1H, 
Olefin), (5.21 (s, 2H, CH2Ar), 5.41-5.62 (m,1H, CH2CHO), 2.78-3.05 (m, 2H, CH2CHN3); 
13
C-NMR (75.5 MHz, CDCl3):  = 172.31 (Cquart, CO), 154.22 (Cquart, COOAr), 132.50 (Ar-
C), 128.82 (Ar-C), 112.26 (CN), 78.80 (CH2CHO), 65.40 (CH2Ar),  38.16 (CH2CHN3), 
35.22 (CH2COOAr); IR (Film): 
~   = 2924, 2229, 2200, 1738, 1612, 1389, 1270, 1158, 1109, 
817, 548 cm
-1
.   MS [Cl, NH3]: m/z (%) 257.0 [M
+.
]; HRMS (Cl, NH3); Calculated for 
[C14H11NO4]:  257.0690, found 257.0688.  
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N3
O
O
NO2
133  
4-Nitrobenzyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate (133, CDCl3) 
To a stirred solution of azido carboxylic acid 121 (50.0 mg, 0.27 mmol) in dry DMF (2 mL) 
was added NaHCO3 (90.7 mg, 4 equiv.), followed by 4-nitro bromo benzyl (93.3 mg, 1.6 
equiv.) sequentially at room temperature under nitrogen atmosphere. The reaction mixture 
was stirred for 24 h at room temperature. Then the mixture was diluted with   4 mL of DCM: 
H2O (1:1) solution and the solution was separated. The aqueous layer  extracted with DCM 
and the combined organic layer was dried over by MgSO4, concentrated under reduced 
pressure to give yellowish crude oil product, which was purified by column chromatography 
on silica gel (petroleum:ethyl acetate, 6:4) to yield  35.0 mg (41%) of 133 as white solid and 
side product 134  7.0 mg (10%) as yellowish oil 
 
Rf = 0.24   (SiO2, petroleum:ethyl acetate 6:4); m.p. 80-82 °C  20D = +47.7 (c = 0.34, 
CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 8.21-8.34 (dd, J = 8.78, 1.6 Hz, 2H, Ar), 7.51-7.57 (dd, J = 
8.78, 1.3 Hz, 2H, Ar ),  5.27(s, 2H, CH2Ar), 4.87-4.95 (m,1H, CH2CHO), 4.55-4.60 (m, 1H, 
N3CH), 2.87-3.06 (m, 3H, CH2CHN3, CH2COOAr), 2.68 (dd, J = 17.8, 1.4 Hz, CH2CN3); 
13
C-NMR (75.5 MHz, CDCl3):  = 172.67 (Cquart, CO), 169.19 (Cquart, COOAr), 147.86 
(Cquart, Ar), 142.37 (Cquart, Ar), 128.72 (Ar-C), 123.93 (Ar-C), 77.80 (CH2CHO), 67.08  
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(CH2Ar), 59.48 (CHN3), 35.56 (CH2CHN3), 34.22 (CH2COOAr); IR (Film): 
~   = 2142, 
2106, 1771, 1728, 1608, 1521, 1414, 1346, 1315, 1287, 1200, 1151, 1120, 992, 848, 741, 
692 cm
-1
.   MS [Cl, NH3]: m/z (%) 264.9 [M + HCOO
-
]; HRMS (Cl, NH3); Calculated for 
[C13H12N4O6]:  320.2611, found 320.2601.  
 
OO O
O
NO2
134  
(S)-4-Nitrobenzyl 2-(5-oxo-2,5-dihydrofuran-2-yl)acetate (134, CDCl3)  
Rf = 0.20  (SiO2, petroleum ether/ethylacetate 6:4);  20D = +26.4 (c = 0.4, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 8.21-8.29 (dd, J = 8.78, 1.6 Hz, 2H, Ar), 7.61-7.64 (dd, 
1H, J = 4.8, 1.7 Hz, 1H, CHCHCO),  7.52-7.58 (dd, J = 8.78, 1.4 Hz, 2H, Ar ), 6.15-6.20 
(dd, J = 5.8, 1.9 Hz, 1H, CHCO), 5.25 (s, 2H, CH2Ar),  4.55-4.65 (m,1H, CH2CHO), 2.87 
(dd, J = 16.4, 7.3 Hz, 1H, CH2COO), 2.69 (dd, J = 16.6, 7.1 Hz, 1H, CH2COO); 
13
C-NMR 
(75.5 MHz, CDCl3):  = 172.58 (Cquart, CO), 169.19 (Cquart, COOAr), 154.87 (Cquart, Olefin), 
147.86 (Cquart, Ar), 142.37 (Cquart, Ar), 128.72 (Ar-C), 123.95 (Ar-C), 122.52 (Cquart, Olefin), 
78.65 (CH2CHO), 65.57 (CH2Ar), 34.22 (CH2COOAr);; IR (Film): 
~  = 2109, 1738, 1606, 
1519, 1345, 1270, 1152, 1110, 1024, 925, 849, 817, 739, 693 cm
-1
. MS [Cl, NH3]: m/z (%) 
295.00 [M + NH4
+
]; Elemental analysis calcd (%) for C13H11NO6 (277.23): C 56.32, H 4.04, 
N 5.05; found C 55.89, H 4.13, N 5.23.  
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135  
 
Benzo[d][1,3]dioxol-5-ylmethyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate 
(135, CDCl3)  
Rf = 0.34 (SiO2, petroleum ether:ethyl acetate:6:41); m.p. 66-68 °C  20D =  +52.7 (c = 0.15, 
CH2Cl2);  
To a stirred solution of azido carboxylic acid 121 (50.0 mg, 0.27 mmol) in dry DMF (2 mL) 
was added NaHCO3 (90.7 mg, 4 equiv.), followed by methylene dioxibromobenzene (185.0 
mg, 1.6 equiv.) sequentially at room temperature under nitrogen atmosphere. The reaction 
mixture was stirred for 24 h at room temperature. Then the mixture was diluted with   4 mL 
of DCM: H2O (1:1) solution and the solution was separated. The aqueous layer  extracted 
with DCM and the combined organic layer was dried over by MgSO4, concentrated under 
reduced pressure to give yellowish crude oil product, which was purified by column 
chromatography on silica gel (petroleum:ethyl acetate, 6:4) to yield  42.0 mg (50%) of 135 as 
white solid and side product 136  10.0 mg (14%) as yellowish oil. 
 
Rf = 0.36 (SiO2, petroleum ether:ethyl acetate:6:41); m.p. 66-68 °C  
20
D = (c = 0.35, 
CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 6.76 (m, 3H, Ar), 5.98 (s, 2H, acetal-CH2), 5.20 (s, 2H, 
CH2Ar), 4.84-4.92 (m,1H, CH2CHO), 4.52-4.56 (m, 1H, N3CH), 2.86-3.12 (m, 3H,  
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CH2CHN3, CH2COOAr), 2.64-2.72 (dd, J = 17.8, 1.4 Hz, CH2CN3); 
13
C-NMR (75.5 MHz, 
CDCl3):  = 172.84 (Cquart, CO), 169.31 (Cquart, COOAr), 147.86 (Cquart, Ar), 128.72 (Cquart, 
Ar-C), 122.60 (Ar-C), 109.16 (Ar-C), 108.35 (Ar-C), 101.29 (acetal-CH2), 78.03 (CH2CHO), 
67.08 (CH2Ar), 59.61 (CHN3), 35.66 (CH2CHN3), 34.26 (CH2COOAr); IR (Film): 
~   = 
2132, 2098, 1777, 1720, 1501, 1443, 1411, 1348, 1311, 1276, 1249, 1191, 1150, 1121, 1029, 
932, 823, 786 cm
-1
.   MS [Cl, NH3]: m/z (%) 319.0 [M
+.
]; HRMS (Cl, NH3); Calculated for 
[C14H13N3O6]:  319.0804, found 319.0850.  
 
OO O
O
O
O
136  
 
Rf = 0.31 (SiO2, petroleum ether:ethyl acetate:6:4);  20D = +2.7 (c = 0.35, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 7.54-7.60 (dd, J = 5.6, 1.5 Hz,1H, CHCHCO),  6.75-6.79 
(m, 3H, Ar ), 6.16-6.18 (dd, J = 6.16, 2.0 Hz,1H, CHCO ), 5.98  (s, 2H, acetal-CH2),  5.38-
5.45 (m,1H, CH2CHO), 5.20 (s, 2H, CH2Ar), 2.86-2.90 (dd, dd, J = 16.6, 7.3 Hz, 1H, 
CH2COOAr), 2.64-2.72 (dd, J = 17.8, 1.4 Hz, CH2COOAr); 
13
C-NMR (75.5 MHz, CDCl3): 
 = 172.79 (Cquart, CO), 169.30 (Cquart, COOAr), 155.28 (Cquart, olefin), 147.86 (Cquart, Ar), 
128.72 (Cquart, Ar-C), 122.60 (Ar-C), 122.2 (Cquart, olefin), (109.21 (Ar-C), 109.17 (Ar-C), 
109.16 (Ar-C), 101.29 (acetal-CH2), 78.84 (CH2CHO), 67.10 (CH2Ar), 35.66 (CH2COOAr); 
IR (Film): ~   = 2132, 2098, 1777, 1720, 1501, 1443, 1411, 1348, 1311, 1276, 1249, 1191,  
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1150, 1121, 1029, 932, 823, 786 cm
-1
. MS [Cl, NH3]: m/z (%) 276.0 [M
+.
]; HRMS (Cl, 
NH3); Calculated for [C14H12O6]:  276.0634, found 276.0632.  
 
 
OO
N3 O
O
137  
 
 
Isopropanol2-((2S,3S)-3- Azido-5-oxotetrahydrofuran-2-yl)-N-(1-phenylethyl)acetamide 
(137)  
 
To a stirred solution of azido carboxylic acid 121 (50.0 mg, 0.27 mmol) in isopropanol (5 
mL) was added concentrated H2SO4 (catalytic amount) and the reaction mixture was refluxed 
for 2 h. The solvent was removed by rotary evaporator. Then the reaction mixture was 
dissolved in CH2Cl2 (5 mL), washed with saturated NaHCO3 (5 mL) and brine (5 mL). The 
organic layer was dried over by MgSO4 and the solvent was evaporated under reduced 
pressure to give yellowish oily crude product, which was purified by column 
chromatography on silica gel (petroleum ether: ethyl acetate, 6:4) to yield  54.0 mg  (90%) of 
137 as colorless oil and side product 2 mg (5%) 138 as yellowish oil. 
 
Rf = 0.62 (SiO2, petroleum ether: ethyl acetate, 6:4);  
20
D = +17.7 (c = 0.4, CH2Cl2); 
1
H-NMR (300 MHz, CDCl3):  = 5.00-5.10 (m, 1H, CHCH3), 4.83-4.92 (m, 1H, CH2CHO), 
4.54-4.60 (m, 1H, CHN3), 2.63-2.95 (m, 4H, CH2CHN3, CH2CON), 1.26 (d, J = 6.6 Hz,  
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CH3); 
13
C-NMR (75.5 MHz, CDCl3):  = 172.98 (Cquart, CO), 169.00 (Cquart, CO), 78.27 
(CH2CHO), 68.98 (Cquart,CH3-C), 59.78 (CH2CHN3), 35.73 (CH2CHN3), 34.52 (CH2CHO),  
21.74 (CH3); IR (Film): 
~  = 2983, 2104, 1781, 1721, 1309, 1268, 1182, 1148, 1104, 1021, 
962, 668, 548 MS [Cl, NH3]: m/z (%) 228.1 [M + H
+
]; HRMS (Cl, NH3); Calculated for 
[C14H16N4O3]: 227.2172, found 227.0984.  
 
 
 
Rf = 0.2 (SiO2, petroleum ether: ethyl acetate, 6:4);  20D =  +30.2 (c = 0.3, CH2Cl2); 
1
H-NMR (300 MHz, CDCl3):  = 7.58-7.62 (dd, J =5.76, 1.4 Hz, 1H), 6.16-6.20 (dd, J = 
5.62, 2.1 Hz, 1H), 5.32-5.44 (m, 1H, CHCOO), 4.83-4.92 (m, 1H, CH2CHO), 2.87- 29.2 (m, 
1H, CH(CH3)2), 2.87-2.92 (dd, J = 16.6, 6.9 Hz, 1H), 2.59-2.69 (dd, J = 16.3, 7.0 Hz, 1H) 
1H, CH2COO), 1.82-1.89(d, J =  6.6 Hz, CH3); 
13
C-NMR (75.5 MHz, CDCl3):  = 172.06 
(Cquart, CO), 165.30 (Cquart, CO), 158.43 (Cquart, CO), 122.56 (CH-Olefin),  78.24 (CH2CHO), 
67.96 (Cquart,CH3-C), 30.91 (CH2CHO), 21.04 (CH3), 14.18 (CH3); IR (Film): 
~  = 2983, 
2104, 1781, 1721, 1680, 1268, 1182, 1148, 1104, 1021, 962, 668, 548 MS [Cl, NH3]: m/z 
(%)  185.1 [M + H
+
];  
 
 
 
 
 
 112 
 
OO O
O
NH
OO
139
 
Benzyl 2-((2S,3S)-3-(tert-Butoxycarbonylamino)-5-oxotetrahydrofuran-2-yl) acetate 
(139) 
To a stirred mixture of azido benzyl ester 120 (128.0 mg, 0.11 mmol, 1 equiv.) in   2 mL dry 
ethanol, was added tert-butoxycarbonyl (Boc2O) (35.6 mg, 0.16 mmol, 1.5 equiv.) and 20% 
Pd(OH)2/C (1.2 mg) at room temperature. Then to this mixture, triethylsilane (30.0 μL, 0.19 
mmol, 1.7 equiv.) was added sequentially and the mixture was stirred for 20 h under N2 
atmosphere. The mixture was filtered through Celite and the filtrate was concentrated under 
reduce pressure to remove the solvent to give white solid which was purified by column 
chromatography on silica gel (petroleum ether: ethyl acetate,) to yield 48.2 mg (71%) of 139 
as white solid. 
Rf = 0. 51 (SiO2, petroleum ether/ethyl acetate 6:4); m.p. 122-124 °C  
20
D = -31.4 (c = 0.4, 
CH2Cl2);  
 
1
H-NMR (300 MHz, CDCl3):  = 7.30-7.55 (m, 5H, Ph), 5.15 (d, J = 2.2 Hz, 2H, CH2Ph), 
4.97-5.35 (m, 1H, CHOCO), 4.86-4.95 (m, 1H, CHNBoc), 4.65 (bs, 1H, NH), 2.93-3.05 (m,  
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1H, CH2CHNBoc), 2.89 (dd, J = 7.1, 3.6 Hz, 1H, CH2COBz), 2.81 (dd, J = 6.3, 1.9 Hz, 1H, 
CH2COBz), 2.48 (dd, J = 17.8, 3.0 Hz, 1H, CH2CHNBoc), 1.43 (s, 9H, Si(CH3)3); 
13
C-NMR  
(75.5 MHz, CDCl3):  = 169.61 (Cquart, CO), 169.34 (Cquart, COBz), 157.4 (Cquart, Boc), 
135.28 (Cquart, Ph), 128.72 (Ph-C), 128.67 (Ph-C), 128.62 (Ph-C), 12.52 (Ph-C), 128.44 (Ph-
C), 79.13 (CHOCO), 78.04 (Cquart, Boc), 67.08 (CH2Ph), 59.59 (CHNBoc), 35.96 
(CH2CHNBoc), 34.52 (CH2COBz), 28.24 (Si(CH3)3); IR (Film): 
~  = 2133, 2100, 1774, 
1717, 1680, 1421, 1311, 1275, 1238 1202, 1151, 1123, 989, 964, 938, 899, 751, 711 cm
-1
. 
MS [Cl, NH3]: m/z (%) 367.0 [M + NH4
+
], 350.0 [M + H
+
] ; Elemental analysis calcd (%) 
for C18H23NO6 (349.38): C 61.88, H 6.64, N 4.01; found C 62.04, H 6.74, N 3.94. 
 
 
 
O
O
NHBoc
O
OH
141  
 
2-((2S,3S)3-(tert-Butoxycarbonylamino)-5-oxotetrahydrofuran-2-yl)acetic acid   (141) 
To a solution of 139 (100.0 mg, 0.11 mmol) in dry EtOH (5 mL) was added Pd/C (1.2 mg, 10 
mol%). The reaction mixture was stirred for 8 h under H2 (1 atm.) at room temperature, 
filtered through celite, dried over MgSO4, concentrated in vacuo to give a crude residue 
which was purified by column chromatography on silica (ethyl acetate/methanol, 1:1) to 
afford 75.3 mg of 141 (95 %) as colorless solid. 
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Rf = 0. 14 (SiO2, petroleum ether/ethylacetate 6:4); m.p. 156-158 °C  20D = +10.0   (c = 0.2, 
DMSO) 
1
H-NMR (300 MHz, D2O):  = 4.91 (m, 1H, CHCH2COOH), 4.39 (m, 1H, CHNBoc), 2.41-
2.45 (m, 4H, CH2COOH, CH2CO), 1.34 (s, 9H, Boc).
 13
C-NMR (75.5 MHz, CDCl3):  IR 
(Film):  ~  = 3362, 2982, 2930, 1773, 1737, 1681, 1522, 1368, 1246, 1154, 1043, 934, 852 
cm
-1
.MS [Cl, NH3]: m/z (%) 259.0[M
+.
]; HRMS (Cl, NH3); Calculated for [C17H17NO6]:  
259.01103, found 259.01113.  
 
 
OO O
O
NH
OO
140  
 
Methyl 2-((2S,3S)-3-(tert-Butoxycarbonylamino)-5-oxotetrahydrofuran-2-yl) acetate  
(140) 
To a stirred mixture of azido methyl ester 128 (236 mg, 1.18 mmol, 1 equiv.) in 13 mL dry 
ethanol, was added tert-butoxycarbonyl (Boc2O) (647 mg, 2.96 mmol, 2.5 equiv.) and 20 % 
Pd(OH)2/C (11.8 mg) at room temperature. Then to this mixture, triethylsilane (0.28 ml, 1.80 
mmol, 1.5 equiv.) was added sequentially and the mixture was stirred for 24 h under N2 
atmosphere. The mixture was filtered through Celite and the filtrate was concentrated under 
reduce pressure to remove the solvent to give white solid which was purified by column  
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chromatography on silica gel (petroleum ether: ethyl acetate, 4:6 ) to yield  239.9  mg (74%) 
of 140 as white solid. 
 
Rf = 0.66   (SiO2, petroleum ether/ethyl acetate 6:4); m.p. 119-121 °C  20D = -42.1     (c = 
0.4, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 5.14 (d, J = 8.8 Hz, 1H, CHOCO), 4.97 (m, 1H, 
CHNBoc), 4.62 (bs, 1H, NH), 3.72 (s, 3H, OCH3), 2.90-2.98 (dd, J = 18.3, 8.4 Hz, 1H, 
CH2CHNBoc), 2.77 (d, J = 6.6, Hz, 2H, CH2COOCH3), 2.49 (dd, J = 18.1, 3.3 Hz, 1H, 
CH2CHNBoc), 1.43 (s, 9H, Si(CH3)3); 
13
C-NMR (75.5 MHz, CDCl3):  = 174.33 (Cquart, 
CO), 170.21 (Cquart, COOCH3), 157.0 (Cquart, CO-Boc), 80.52 (CHOCO), 79.28 (Cquart, Boc), 
52.20 (CHNBoc), 49.48 (OCH3), 35.95 (CH2CHNBoc), 34.26 (CH2COOCH3), 28.24 
(Si(CH3)3); IR (Film):  
~  = 3359, 3010, 1774, 1735, 1681, 1522, 1356, 1296, 1249, 1180, 
1051, 935, 853, 779, 617 cm
-1
. MS [Cl, NH3]: m/z (%) 291.1 [M + NH4
+
], 274.0 [M + H
+
]; 
HRMS (Cl, NH3); Calculated for [C12H19NO6:  273.1212, found 273.1209. 
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2.3            Synthesis of dipeptide and tetramer 
 
O
O
N3 O
N
H O
O
177  
 
 
 
Benzyl2-(2-((2S,3S))-3-Azido-5-oxotetrahydrofuran-2-yl)acetamido)-4-ethylpentanoate 
(177) 
To a stirred solution of azido carboxylic acid 121 (157.0 mg, 0.85 mmol) in dry THF (4 mL) 
was added HOBt (125.6 mg, 1.1 equiv.), HBTU (417.2 mg, 1.3 equiv.) and amine 178 (0.299 
mg, 1.1 equiv.) at 0 
o
C. Then the ice bath was removed and the reaction mixture was stirred 
for 24 h at room temperature. The solvent was removed by rotary evaporator. Then the 
reaction mixture was dissolved in CH2Cl2 (5 mL), washed with 1 M KHSO4 (5 mL), 5% 
NaHCO3 (5 mL) and brine (5 mL). The organic layer was dried over by MgSO4 and the 
solvent was evaporated under reduced pressure to give white solid crude product, which was 
purified by column chromatography on silica gel (ethyl acetate: methanol, 14:1) to yield  
0.190 mg  (60%) of 177 as crystalline solid. 
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Rf = 0.88   (SiO2,); (ethyl acetate: methanol, 14:1) m.p. 126-128 
o
C  20D = +20.9 (c = 0.4, 
CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 7.28-7.40 (m, 5H, Ph), 6.17 (d, 1H, J = 9.3 Hz, NH), 5.16 
(d, 2H, J = 2.2 Hz, 2H, CH2Ph), 4.85-4.93 (m, 1H, CHNH), 4.62-4.71 (m, 1H, CH2CHO), 
4.45-4.60 (m, 1H, CH2CHN3), 2.62-2.93 (m, 4H, CH2CHN3, CH2CON), 1.52-1.71 (m, 3H, 
CHCH3, CH2CHCH3), 0.92 (d, J = 6.0 Hz, CH3); 
13
C-NMR (75.5 MHz, DMSO):  = 173.03 
(Cquart, CO), 172.55 (Cquart, CO), 168.18 (Cquart, CO), 135.28 (Cquart, Ph), 128.64 (Ph-C), 
128.51 (Ph-C), 128.30 (Ph-C),  78.94 (CH2CHO), 67.24 ( CH2Ph), 59.86 (CH2CHNH), 51.03 
(CH2CHN3), 41.38 (CH2CHCH3), 36.07 (CH2CHN3), 35.88 (CH2CHO), 24.86 (CHCH3), 
22.76 (CH3), 21.87 (CH3); IR (Film):  
~  =3360, 2955, 2133, 2097, 1778,1708,1668, 1536, 
1288, 1256, 1150, 1028, 999, 739 cm
-1
.  MS [Cl, NH3]: m/z (%) 389.0 [M + H
+
]; HRMS (Cl, 
NH3); Calculated for [C19H24N4O5]: 388.1735, found 388.1747. 
 
 
 
 
 
 
 
 
 
Benzyl2-(2-((2S,3S))-3-Azido-5-oxotetrahydrofuran-2-yl)acetamido)-4-ethylpentanoate 
(176) 
To a stirred mixture of azido ester 177 (236 mg, 1.18 mmol, 1 equiv.) in 13 mL dry ethanol, 
was added tert-butoxycarbonyl (Boc2O) (647 mg, 2.96 mmol, 2.5 equiv.) and 20%  
 
 
OO
NHBoc
O
N
H O
O
176  
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Pd(OH)2/C (11.8 mg) at room temperature. Then to this mixture, triethylsilane (0.28 mL, 
1.80 mmol, 1.5 equiv.) was added sequentially and the mixture was stirred for 24 h under N2 
atmosphere. The mixture was filtered through Celite and the filtrate was concentrated under 
reduce pressure to remove the solvent to give white solid which was purified by column 
chromatography on silica gel (petroleum ether: ethyl acetate, 4:6) to yield 239.9 mg (74%) of 
176 as yellowish oil 
 
Rf = 0.65   (SiO2,); (petroleum ether: ethyl acetate, 2:8)  20D = -20.9   (c = 0.3, CH2Cl2);  
1
H-NMR (300 MHz, CDCl3):  = 7.30-7.40 (m, 5H, Ph), 6.58-6.70 (d, 1H, J = 9.0 Hz, NH), 
5.60-5.71 (d, 1H, J = 10.1 Hz, NH), 5.17 (s, 2H, CH2Ph), 4.81-4.90 (m, 1H, CHO), 4.51-4.71 
(m, 1H, CH2CHCOO, CH2CHNHBoc), 2.40-2.93 (m, 4H, CH2CHN3, CH2CON), 1.52-1.71 
(m, 3H, CHCH3, CH2CHCH3), 1.40 (s, 9H, (CH3)3), 0.92 (d, J = 6.0 Hz, CH3); 
13
C-NMR 
(75.5 MHz, DMSO):  = 174.40 (Cquart, CO), 169.08 (Cquart, CO), 168.27 (Cquart, CO), 168.18 
(Cquart, CO), 135.28 (Cquart, Ph), 128.64 (Ph-C), 128.35 (Ph-C), 128.30 (Ph-C),  85.22 
(CH2CHO), 79.74 (Cquart, Boc), 67.22 ( CH2Ph), 59.86 (CHNHBoc), 51.22 (CH2CHO), 41.34 
(CH2CHCH3), 36.54 (CH2CHNHBoc), 35.92 (CH2CHO), 28.31 (Si(CH3)3, 24.84 (CHCH3), 
22.80 (CH3), 21.80 (CH3); IR (Film): 
~  =3310, 2924, 2855, 1737,1661,1535, 1457, 1366, 
1253, 1165, 1028, 743, 687 cm
-1
.  MS [Cl, NH3]: m/z (%) [M + H
+
]; HRMS (Cl, NH3); 
Elemental analysis calcd (%) for C24H34N2O7 (241.1): C 62.3, H 7.41, N 6.06 ; found C 
61.52, H 7.73,  N 5.86. 
 
 
 
 119 
 
 
O
O
BocHN
O
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O
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O
O
HN
O
OO
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(R)-Benzyl2-(2-((2S,3R)-3-((R-2-(2-((2S,3S)-3-(tert-butoxycarbonylamino)-5-
oxotetrahydrofuran-2-yl)acetamido)-4-methylpentanamido)-5-oxotetrahydrofuran-2-
yl)acetamido)-4-methylpentanoate (173) 
 
To a stirred solution of 174 (25.0 mg, 0.067 mmol, 1 equiv.) in dry THF (3 mL) at 0 
o
C was 
added sequentially HBTU (27.9 mg, 0.087 mmol, 1.3 equiv.) and HOBt (11.8 mg, 0.087 
mmol, 1.1 equiv.). After 30 min, to this reaction mixture was added a solution of 175 ( 25.5 
mg, 0.073 mmol, 1.1 equiv.), MgSO4 (200 mg, 1.67 mmol, 25 equiv.), NaHCO3 (500 mg, 5.9 
mmol, 88.0 equiv.) in CH3CN (3 mL)  and stirred for 3 d at room temperature. The reaction 
mixture was diluted with CH2Cl2 (10 mL), washed with 1 M KHSO4 (5 mL), saturated 
NaHCO3 (15 mL) and saturated NaCl (20 mL), dried over MgSO4, filtered and concentrated 
in vacuo to give yellowish oil which was purified by column chromatography on silica  ( 
ethyl acetate/ methanol 1:1) to afford 173 (45.2 mg, 95 %) as an amorphous solid. 
 
Rf = 0.29   (SiO2,); (ethyl acetate, methanol 14:1) m.p. 110-112 
o
C  20D = -16.0 (c = 0.1, 
MeOH ); 
 
1
H-NMR (300 MHz, MeOD):  = 8.67-8.31 (m, 2H, NH), 8.21-8.15 (d, 1H, J = 6.3 Hz, NH), 
7.42-7.44 (m, 1H, NH), 7.29-7.39 (m, 5H, Ph), 5.13 (s, 2H, CH2Ph), 4.98-5.06 (m, 2H, 
CHO), 4.65-4.55 (m, 1H, CHCH2CO), 4.43-4.20 (m, 3H, CHCH2CO, CH2CHNH), 3.02-2.80 
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(m, 2H, CH2CHO), 2.64-2.20 (m, 6H, CH2CHO, CH2CHN), 178-1.58 (m, 6H, CHCH3, 
CH2CHCH3), 1.28 (s, 9H, (CH3)3), 0.83-1.00 (m, CH3); 
13
C-NMR (75.5 MHz, MeOD):  = 
174.83 (Cquart, CO), 174.73 (Cquart, CO), 172.45 (Cquart, CO), 172.25 (Cquart, CO), 169.00 
(Cquart, CO), 168.80 (Cquart, CO), 155.22 (Cquart, CO-Boc), 135.81 (Cquart ), 128.33 (Cquart, Ph), 
127.93 (Ph-C), 127.66 (Ph-C), 79.58 (CH2CHO), 79.26 (CH2CHO), 78.18 (Cquart-Boc), 65.79 
(CH2Ph), 59.65 (CHNH), 50.84 (CH2CHN), 47.89 (CH2CHN), 40.67 (CH2NH), 40.19 
(CH2NH), 35.34 (CH2CHNH),  34.72 (CH2CONH) 34.62 (CH2CONH),  28.04 (CH(CH3)2,  
23.04 (CH3), 22.56 (CH3), 21.46 (CH3), 21.19 (CH3), 13.97 (Si(CH3)3; IR (Film):  
~  =3433, 
1650, 1539, 1419, 1325, 1157, 1041, 818, 753, 559 cm
-1
.  MS [Cl, NH3]: m/z (%) 717.4 [M + 
H
+
]; HRMS, (Cl, NH3); Calculated for [C36H52N4O11]:  716.8201, found 716.8210.  
 
 
 
 
O
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O
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(R)-2-(2-((2S,3R)-3-((R)-2-(2-((2S,3S)-3-(tert-Butoxycarbonylamino)-5-oxotetrahydrofuran-2-yl)
acetamido)-4-methylpentanamido)-5-oxotetrahydrofuran-2-yl)acetamido)-4-methylpentanoic 
acid (181)
 
 
To a solution of 173 (25.0 mg, 0.035 mmol) in dry EtOH (4 mL) was added Pd/C (10 mol 
%). The reaction mixture was stirred for 8 h under H2 (1 atm.) at room temperature, filtered 
through celite, dried over MgSO4, concentrated in vacuo to give a crude residue which was  
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purified by column chromatography on silica (dichloromethane/methanol 1:1) to afford 28.8 
mg (90 %) of 181  as colorless solid. 
 
Rf = 0.23   (SiO2,); (ethyl acetate, methanol 14:1) m.p. 154-158 
o
C  20D = +24.4 (c = 0.1, 
DMSO); 
 
1
H-NMR (300 MHz, MeOD):  = 5.06-5.12 (m, 1H, CHO), 4.97-4.87 (m, 1H, CHO), 4.79-
4.97 (m, 2H, CHCH2CO), 4.40-4.58 (m, 2H, CHNH), 3.01-3.20 (m, 2H, CH2CHN), 2.62-
2.88 (m,6, CH2CHN, CH2CON), 1.50-1.78 (m, 6H, CHCH3, CH2CHCH3), 1.28 (s, 9H, 
(CH3)3), 0.83-1.00 (m, CH3); 
13
C-NMR (75.5 MHz, MeOD):  = 170.31 (Cquart, CO), 167.26 
(Cquart, CO), 166.21 (Cquart, CO), 164.52 (Cquart, CO), 129.60 (Cquart, Ph), 129.38 (Ph-C), 
129.05 (Ph-C), 80.66 (CH2CHO), 78.13 (CH2CHO), 52.33 (CHNH), 52.34 (CH2CHCOO), 
51.62 (CH2CHCOO), 49.42 (CHNH), 33.02 (CH2CONH), 30.82 (CH(CH3)2, 29.80 
(CH(CH3)2,  23.72 (CH3), 23.33 (CH3), 22.21 (CH3), 21.52 (CH3), 14.45 (Si(CH3)3; IR 
(Film):  ~  =3433, 2901, 1650, 1539, 1419, 1325, 1157, 1041, 818, 753, 559 cm
-1
.  MS [Cl, 
NH3]: m/z (%) 627.32 [M + H
+
];  
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Benzyl2-(3-(2-((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(3-(2,2,5,7,8-
pentamethylchroman-6-ylsulfonyl)guanidino)pentanamido)-5-oxotetrahydrofuran-2-
yl)acetate (182) 
 
The compound 139 (45.0 mg, 0.12 mmol) was treated with TFA in dichloromethane (2 mL, 
30 %) at 0 
o
C for 3 h. The solvent was removed in vacuo, to give the salt of 139a as colorless 
solid. To a stirred solution of NFmocArgnine acid 183 (109.0 mg, 164 mmol, 1 equiv.) in dry 
THF (2 mL at 0 
o
C was added sequentially HBTU (79.8 mg, 0.21 mmol, 1.3 equiv.) and 
HOBt (24.0 mg, 0.18 mmol, 1.1 equiv.). After 30 min, to this reaction mixture was added a 
solution of 139a (30.5 mg, 0.064 mmol, 1.1 equiv.) in CH3CN (2 mL) followed by DIPEA 
(0.05 mL) and stirred for overnight at room temperature. The reaction mixture was diluted 
with CH2Cl2 (10 mL), washed with 1 M KHSO4 (5 mL), saturated NaHCO3 (15 mL) and 
saturated NaCl (20 mL), dried over MgSO4, filtered and concentrated in vacuo to give white  
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solid which was purified by column chromatography on silica  ( ethyl acetate/ methanol 1:1) 
to afford 182 (101.0 mg, 68  %) as an amorphous white solid. 
 
 
Rf = 0.24   (SiO2,); (ethyl acetate, petroleum ether 8:2) m.p. 152-154 
o
C  20D = +17.0    (c = 
0.1, MeOH); 
 
1
H-NMR (300 MHz, MeOD):  =  1H-NMR (300 MHz, MeOD):  = 7.70-7.85 (d, 2H, J = 
7.1 Hz, Ar), = 7.67-7.73 (d, 2H, J = 6.9 Hz, Ar), 7.15-7.43 (m, 9H, Ar), 5.10-5.23 (s, 2H, 
CH2Ph), 5.10-5.35 (m, 1H, CHO), 4.66-4.76 (m, 1H, CHAr), 4.28-4.44 (m, 2H, CH2Ar), 
4.15-4.20 (m, 2H, CH2CHNH, CHCH2CH2), 2.95-3.22 (m, 3H, CH3),  2.43-2.74 (m, 10H, 
CH2CHN, CH2CON,CH2C(CH3)2, CH2CH2C(CH3)2), CH2NH), 1.72-1.81 (m, 2H, 
CH2CH2NH), 1.43-1.60 (m, 2H, CH2CH2CH2NH), 1.20-1.34 (m, 12H, CH3); 
13
C-NMR (75.5 
MHz, MeOD):  = 173.06 (Cquart, CO), 167.43 (Cquart, CO), 167.26  (Cquart, CO), 154.70 
(Cquart, CO), 142.64 (C-Ar), 136,59 (C-Ar), 136.08 (C-Ar), 129.60 (C-Ar), 129.53 (C-Ar), 
129.37 (C-Ar), 129.20 (C-Ar), 128.85 (C-Ar), 128.25 (C-Ar), 126.24, (C-Ar) 125.03 (C-Ar), 
120.98 (C-Ar), 119.03 (C-Ar),  81.35 (Cquart), 79.44 (CH2CHO), 74.89 (CH2-Fmoc),  68.08 
(CH2Ph), 67.81 (CHNH), 64.57 (Cquart.) 58.84 (CHNH), 49.93, (CH-Fmoc), 33.67 (CH2), 
31.66 (CH2), 27.00 (CH2), 22.40 (CH2), 20.97 (CH2), 19.08  (CH3), 18.00 (CH3), 17.82  
(CH3), 14.46 (CH3) , 12.38 (CH3); IR (Film):  
~  =3488, 1623, 1703, 1632, 1546, 1421, 1330, 
1165, 1107, 1040, 818, 741, 597 cm
-1
.  MS [Cl, NH3]: m/z (%) 804.4 [M + H
+
]; IR (Film):  
~  =3488, 1703, 1623, 1546, 1421, 1330, 1165, 1107, 1040, 818, 741, 658 cm
-1
.  MS [Cl, 
NH3]: m/z (%) 894.4 [M + H
+
];  
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2-(3-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-5-(3-(2,,2,5,7,8-pentamethylchroman-
6-yl sulfonyl)guanidine)pentanamido)-5-oxotetrahydrofuran-2-yl)acetic acid (184) 
 
To a solution of 182 (100.0 mg, 0.11 mmol) in dry EtOH (5 mL) was added Pd/C (1.2 mg, 10 
mol%). The reaction mixture was stirred for 8 h under H2 (1 atm.) at room temperature, 
filtered through celite, dried over MgSO4, concentrated in vacuo to give a crude residue 
which was purified by column chromatography on silica (ethyl acetate/methanol, 1:1) to 
afford 67.3 mg of 184 (95 %) as colorless solid. 
 
Rf = 0.23 (SiO2,); (ethyl acetate, methanol 14:1) m.p. 184-186 
o
C  20D = +8.3   (c = 0.1, 
DMSO);  
 
1
H-NMR (300 MHz, DMSO):  = 7.71-7.84 (d, 2H, J = 7.1 Hz, Ar), 7.65-7.74 (d, 2H, J = 
6.9 Hz, Ar), 7.25-7.33 (m, 4H, Ar), 5.11-5.23 (m, 1H, CHO), 4.65-4.76 (m, 1H, CHAr), 
4.27-4.46 (m, 2H, CH2Ar), 4.15-4.19 (m, 2H, CH2CHNH, CHCH2CH2), 2.94-3.22 (m, 3H, 
CH3),  2.42-2.79 (m, 10H, CH2CHN, CH2CON,CH2C(CH3)2, CH2CH2C(CH3)2), CH2NH),  
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1.73-1.84 (m, 2H, CH2CH2NH), 1.42-1.61 (m, 2H, CH2CH2CH2NH), 1.21-1.36 (m, 12H, 
CH3); 
13
C-NMR (75.5 MHz, MeOD):  = 173.07 (Cquart, CO), 167.41 (Cquart, CO), 167.25  
(Cquart, CO), 154.70 (Cquart, CO), 142.56 (C-Ar), 136,49 (C-Ar), 136.05 (C-Ar), 128.76 (C-
Ar), 128.15 (C-Ar), 126.17 (C-Ar), 124.94 (C-Ar), 120.87 (C-Ar), 119.36 (C-Ar),  81.32 
(Cquart), 79.43 (CH2CHO), 74.82 (CH2-Fmoc), 67.81 (CHNH), 58.8 (CHNH), 49.84 (CH-
Fmoc), 33.69 (CH2), 30.66 (CH2), 26.88 (CH2), 22.30 (CH2), 20.83  (CH2), 18.92  (CH3), 
18.31  (CH3), 17.83  (CH3), 14.41 (CH3) , 12.20 (CH3); IR (Film):  
~  =3487, 1623, 1543, 
1448, 1325, 1158, 1108, 1041, 813, 742, 567 cm
-1
.  MS [Cl, NH3]: m/z (%) 804.4 [M + H
+
];  
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((1R,6R)-6-Azidocyclohex-3-enyloxy)trimethylsilane (66, CDCl3):  
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     Tert-butyl (1R,6R)-6-(trimethylsilyloxy)cyclohex-3-enylcarbamate (65, CDCl3): 
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Tert-butyl (3R,4R)-1,6-dioxo-4-(trimethylsilyloxy)hexan-3-ylcarbamate (64, CDCl3)
 
 
0
.
5
8
6
0
0
.
7
8
5
8
0
.
5
6
7
1
0
.
7
5
4
8
0
.
5
3
9
7
0
.
5
6
1
3
0
.
6
7
2
1
0
.
6
7
0
3
9
.
0
0
0
0
9
.
0
4
6
9
( p p m )
0 . 01 . 02 . 03 . 04 . 05 . 06 . 07 . 08 . 09 . 0
 
 
( p p m )
02 04 06 08 01 0 01 2 01 4 01 6 01 8 02 0 0
 
 
 
 
 
                                                                    Appendix of NMR   
130 
 
(3aS,6aS)-Tert- butyl 2,5-dioxotetrahydro-2H-furo[3,2-b]pyrrole-4(5H)-carboxylate (63a, 
CDCl3): 
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(3aS,6aS)-tert-butyl 2-oxotetrahydro-2H-furo[3,2-b]pyrrole-4(5H)-carboxylate (75, 
CDCl3) 
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(3aS,6aS)-tert-butyl tetrahydro-2H-furo[3,2-b]pyrrole-4(5H)-carboxylate (79, CDCl3)  
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(3aS,6aS)-hexahydro-2H-furo(3,2-b)pyrrole hydrochloride (36b, MeOD) 
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2-((2S,3S)-3-Azido-5-oxotetrahydrofuran-2-yl)acetic acid (121, DMSO):  
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2-((2S,3S)-3-Azido-5-oxotetrahydrofuran-2-yl)-N-(1-phenylethyl)acetamide (123, 
CDCl3):  
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2-((2S,3S)-3-Azido-5-oxotetrahydrofuran-2-yl)-N-(1-phenylethyl)acetamide (123 
(Racemic), CDCl3 
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Benzyl 2-((2S,3S) )-3-Azido-5-oxotetrahydrofuran-2-yl)acetate (120, CDCl3): 
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(S)-Benzyl 2-(5-oxo-2,5-dihydrofuran-2-yl)acetate (127, CDCl3): 
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Methyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate (128, CDCl3):  
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3-(Trifluoromethoxy)benzyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-
yl)acetate (129, CDCl3) 
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(S)-3-(Trifluoromethoxy)benzyl 2-(5-oxo-2,5-dihydrofuran-2-yl)acetate (130, 
CDCl3) 
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4-Cyanobenzyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate (131, CDCl3) 
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(S)-4-Cyanobenzyl 2-(5-oxo-2,5-dihydrofuran-2-ylIacetate (132, CDCl3) 
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4-Nitrobenzyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate (133, CDCl3) 
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(S)-4-Nitrobenzyl 2-(5-oxo-2,5-dihydrofuran-2-yl)acetate (134, CDCl3)  
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      Benzo[d][1,3]dioxol-5-ylmethyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate      
      (135, CDCl3) 
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Benzo(d)(1,3)dioxol- 5-ylmethyl 2-((2S,3S)-3 azido-5-oxotetrahydrofuran-2-yl)acetate 
(136, CDCl3)  
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Isopropyl 2-((2S,3S)-3-azido-5-oxotetrahydrofuran-2-yl)acetate  (137, CDCl3): 
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Benzyl 2-((2S,3S)-3-(tert-butoxycarbonylamino)-5-oxotetrahydrofuran-2-
yl)acetate (139, CDCl3) 
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Methyl 2-((2S,3S)-3-(tert-butoxycarbonylamino)-5-oxotetrahydrofuran-2-yl)acetate (140, 
CDCl3):  
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2-(2S,3S)-3-(tert-butoxycarbonylamino)-5-oxotetrahydrofuran-2-yl)acetic acid 
(141, CDCl3) 
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Benzyl 2-(2-((2S,3S) )-3-Azido-5-oxotetrahydrofuran-2-yl)acetamido)-4-
methylpentanoate (177, CDCl3): 
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(R)-Benzyl2-(2-((2S,3R)-3-((R-2-(2-((2S,3S)-3-(tert-butoxycarbonylamino)-5-
oxotetrahydrofuran-2-yl)acetamido)-4-methylpentanamido)-5-
oxotetrahydrofuran-2-yl)acetamido)-4-methylpentanoate (173, DMSO) 
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(R)- 2-(2-((2S,3R)-3-((R)-2-(2-((2S,3S)-3-(tert-butoxycarbonylamino)-5-
oxotetrahydrofuran-2-yl)acetamido)-4-methylpentanamido)-5-
oxotetrahydrofuran-2-yl)acetamido)-4-methylpentanoic acid (181, DMSO)  
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Benzyl2-(3-(2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(3-(2,2,5,7,8-
pentamethylchroman-6-ylsulfonyl)guanidine)pentanamido)-5-oxotetrahydrofuran-2-
yl)acetate (182, MeOD) 
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2-(3-(2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(3-(2,2,5,7,8-pentamethylchroman-
6-ylsulfonyl)guanidino)pentanamido)-5-oxotetrahydrofuran-2-yl)acetic acid (184, 
DMSO) 
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Table 1.  Crystal data and structure refinement for gaa.  
 
Crystal Data ;  
 
Empirical formula ;C11 H15 N O5  
 
Formula weight ;241.24  
  
Crystal size ;0.570 x 0.130 x 0.060 mm  
   
Crystal description ;stick  
   
Crystal colour ;translucent colourless  
   
Crystal system;Orthorhombic  
   
Space group ;P 21 21 21  
   
Unit cell dimensions       ;a = 6.38405(13) A   alpha = 90 deg.  
                                        ;b = 10.35543(18) A    beta = 90 deg.  
                                        ;c = 17.7328(3) A   gamma = 90 deg.  
   
Volume ;1172.31(4) A^3  
   
Z, Calculated density ;4,  1.367 Mg/m^3  
   
Absorption coefficient ;0.918 mm^-1  
   
F(000) ;512  
   
   
 Data Collection ;  
   
  Measurement device type ;Goniometer Xcalibur, detector: Ruby (Gemini ultra Mo)  
   
Measuremnet method ;\w scans  
   
Temperature ;123 K  
   
OO
N O
O O
63  
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Wavelength ;1.54184 A  
   
Monochromator ; graphite  
   
Theta range for data collection ;4.95 to 66.65 deg.  
   
Index ranges ;-7<=h<=4, -12<=k<=12, -20<=l<=20  
   
Reflections collected / unique ;6308 / 2049 [R(int) = 0.0333]  
   
Reflections greater I>2\s(I);2018  
   
Absorption correction ;Semi-empirical from equivalents  
   
Max. and min. transmission ;1.00000 and 0.80965  
   
   
Refinement ;  
   
   
Refinement method ;Full-matrix least-squares on F^2  
   
Hydrogen treatment ;:  
   
Data / restraints / parameters ;2049 / 0 / 154  
   
Goodness-of-fit on F^2 ;1.073  
   
Final R indices [I>2sigma(I)]     ;R1 = 0.0311, wR2 = 0.0811  
   
R indices (all data)              ;R1 = 0.0316, wR2 = 0.0820  
   
Absolute structure parameter ;-0.01(17)  
   
Largest diff. peak and hole ;0.158 and -0.190 e.A^-3  
   
Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 
x 10^3) for gaa. U(eq) is defined as one third of the trace of the orthogonalized        Uij tensor.  
   
 
 
 
  
   ;x   ;y    ;z ;U(eq)  
   
O(1);-2420(2);-1514(1);-5368(1);30(1)  
O(2);-7446(2);1048(1);-5593(1);30(1)  
O(3);-7134(2);3083(1);-5205(1);39(1)  
O(4);-1430(2);-712(1);-3901(1);31(1)  
O(5);-4350(2);-72(1);-3280(1);26(1)  
N(1);-4617(2);-523(1);-4497(1);21(1)  
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C(1);-4111(2);-1083(1);-5188(1);24(1)  
C(2);-6065(2);-1106(2);-5663(1);27(1)  
C(3);-7604(2);-242(1);-5268(1);26(1)  
C(4);-7221(2);1954(2);-5053(1);29(1)  
C(5);-7126(2);1326(1);-4289(1);27(1)  
C(6);-6831(2);-107(1);-4449(1);23(1)  
C(7);-3256(2);-453(1);-3883(1);23(1)  
C(8);-3299(2);268(1);-2562(1);28(1)  
C(9);-1836(3);1384(2);-2692(1);42(1)  
C(10);-2219(4);-900(2);-2230(1);48(1)  
C(11);-5145(3);651(2);-2073(1);48(1)  
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Table 1.  Crystal data and structure refinement for j177.  
   
Crystal Data ;  
    
Empirical formula ;C19 H24 N4 O5  
 
Formula weight ;388.42  
   
Crystal size ;0.3912 x 0.1675 x 0.0177 mm  
   
Crystal description ;small plate  
   
Crystal colour ;colourless  
   
Crystal system;Monoclinic  
   
Space group ;P 21  
   
Unit cell dimensions       ;a = 5.55990(9) A   alpha = 90 deg.  
                                        ;b = 15.95341(19) A    beta = 100.6484(14) deg.  
                                        ;c = 11.20045(15) A   gamma = 90 deg.  
   
Volume ;976.37(2) A^3  
   
Z, Calculated density ;2,  1.321 Mg/m^3  
   
Absorption coefficient ;0.806 mm^-1  
   
F(000) ;412  
    
 Data Collection ;  
     
Measurement device type ;SuperNova, Single source at offset), Atlas  
   
Measuremnet method ;\w scans  
   
Temperature ;173 K  
   
O
O
N3 O
N
H O
O
177  
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Wavelength ;1.54184 A  
   
Monochromator ; graphite  
   
Theta range for data collection ;4.02 to 71.34 deg.  
   
Index ranges ;-6<=h<=6, -19<=k<=19, -13<=l<=13  
   
Reflections collected / unique ;9063 / 3543 [R(int) = 0.0212]  
   
Reflections greater I>2\s(I);3421  
   
Absorption correction ;Analytical  
   
Max. and min. transmission ;0.985 and 0.843  
   
Refinement ;  
   
Refinement method ;Full-matrix least-squares on F^2  
   
Hydrogen treatment ;:  
   
Data / restraints / parameters ;3543 / 1 / 256  
   
Goodness-of-fit on F^2 ;1.068  
   
Final R indices [I>2sigma(I)]     ;R1 = 0.0247, wR2 = 0.0647  
   
R indices (all data)              ;R1 = 0.0257, wR2 = 0.0652  
   
Absolute structure parameter ;0.08(12)  
   
Largest diff. peak and hole ;0.115 and -0.130 e.A^-3  
   
Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 
x 10^3) for j177. U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
   
   ;x   ;y    ;z ;U(eq)  
   
O(1);-3392(2);480(1);-10316(1);33(1)  
O(2);-7236(2);738(1);-11266(1);41(1)  
O(3);-3724(2);2814(1);-10360(1);38(1)  
O(4);4600(2);3962(1);-6304(1);42(1)  
O(5);2842(2);3639(1);-8193(1);33(1)  
N(1);-1681(2);1853(1);-11252(1);30(1)  
N(2);-1064(2);2395(1);-7578(1);42(1)  
N(3);-3028(2);2023(1);-7805(1);36(1)  
N(4);-4706(2);1610(1);-7956(1);52(1)  
C(1);-2247(2);-306(1);-8467(1);30(1)  
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C(2);-130(2);169(1);-8193(1);36(1)  
C(3);1662(3);-27(1);-7194(1);41(1)  
C(4);1355(3);-700(1);-6457(1);43(1)  
C(5);-755(3);-1173(1);-6727(1);47(1)  
C(6);-2547(3);-980(1);-7717(1);40(1)  
C(7);-4272(2);-120(1);-9521(1);34(1)  
C(8);-5062(2);866(1);-11130(1);30(1)  
C(9);-3893(2);1468(1);-11915(1);29(1)  
C(10);-3319(2);990(1);-13013(1);32(1)  
C(11);-2426(3);1538(1);-13964(1);40(1)  
C(12);-4401(4);2123(1);-14598(2);65(1)  
C(13);-1447(3);986(1);-14877(2);54(1)  
C(14);-1786(2);2489(1);-10476(1);27(1)  
C(15);658(2);2765(1);-9754(1);34(1)  
C(16);400(2);3467(1);-8881(1);28(1)  
C(17);-1168(2);3295(1);-7916(1);30(1)  
C(18);156(3);3797(1);-6847(1);42(1)  
C(19);2770(2);3812(1);-7018(1);31(1)  
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